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Purpose: To evaluate the inﬂuence of renal function
on the efﬁcacy and safety of the sodium glucose
cotransporter 2 inhibitor luseogliﬂozin (TS-071) in
Japanese patients with type 2 diabetes mellitus (T2DM).
Methods: Study 1 was a 52-week, Phase III study to
evaluate the efﬁcacy and safety of 2.5 mg/d luseogliﬂozin
(or increased to 5 mg/d) in patients with T2DM with
moderate renal impairment. During the initial 24 weeks,
efﬁcacy and safety of luseogliﬂozin were compared with
placebo. Study 2 was a pooled analysis of four 52-week,
Phase III studies of luseogliﬂozin, including Study 1, to
evaluate the efﬁcacy and safety of luseogliﬂozin in
patients with various degrees of renal function. Patients
were stratiﬁed into 3 groups by baseline estimated
glomerular ﬁltration rate (eGFR): normal renal function
(Z90 mL/min/1.73 m2), mild impairment (Z60 too90
mL/min/1.73 m2), and moderate impairment (Z30 to
o60 mL/min/1.73 m2). Patients with moderate impair-
ment were further divided into those with mild-moderate
(Z45 to o60 mL/min/1.73 m2) and moderate-severe
(Z30 too45 mL/min/1.73 m2). In both studies, efﬁcacy
end points included changes in glycated hemoglobin
(HbA1c) level, fasting plasma glucose (FPG) level, and
body weight. The safety end points included adverse
events (AEs) and laboratory parameters.
Findings: In Study 1, HbA1c, FPG, and body
weight signiﬁcantly decreased at Week 24 in patients66treated with luseogliﬂozin compared with patients
treated with placebo, with the decrease in these
parameters also observed with luseogliﬂozin at Week
52. The incidence of AEs was similar between groups.
In Study 2, 1030 patients were included (normal, 275;
mildly impaired, 598; and moderately impaired, 157).
At Week 52, HbA1c, FPG, and body weight were
signiﬁcantly decreased from baseline in all groups. In
between-group comparisons, the decreases in HbA1c
and body weight were signiﬁcantly smaller in patients
with moderate impairment than in those with normal
function; however, the HbA1c-lowering efﬁcacy was
reduced by nearly half, whereas the efﬁcacy of body
weight lowering was not so much diminished in the
moderate impairment group. Furthermore, a scatter
plot showed that changes in HbA1c were more
inﬂuenced by baseline HbA1c than by baseline eGFR.Volume 38 Number 1
M. Haneda et al.The incidence of AEs during 52 weeks was similar
among all groups, with the majority being mild.
Implications: Luseogliﬂozin improved glycemic con-
trol and reduced body weight in all eGFR groups, and
its efﬁcacy on HbA1c lowering was reduced in those
with moderate renal impairment. Luseogliﬂozin was
well tolerated and safe, with no signiﬁcant safety issues
identiﬁed, regardless of baseline eGFR. The study is
registered with Clinical Trials Information/JapicCTI of
the Japan Pharmaceutical Information Center, and the
study registry identiﬁcation numbers are JapicCTI-
111507, JapicCTI-111508, JapicCTI-111509, and
JapicCTI-111543 (Clin Ther. 2016;38:66–88) & 2016
The Authors. Published by Elsevier HS Journals, Inc.
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The number of patients with type 2 diabetes mellitus
(T2DM) is increasing globally, including in Japan,
with prevalence of 387 million worldwide (in 2013)1
and 9.5 million in Japan (in 2012).2 The common
macrovascular and microvascular complications
related to diabetes remain a major concern because
these are closely associated with high mortality and
low quality of life. Among the microvascular
complications, diabetic nephropathy is particularly
challenging given its irreversibility on progression.
Additionally, it is the most common single cause of
end-stage renal disease (ESRD) in Japan, accounting
for 43.8% of new ESRD cases.3 Previous studies have
shown an association between poor glycemic control
and diabetic nephropathy in patients with T2DM,
suggesting that intensiﬁcation of early treatment could
delay the progression of diabetic renal failure.4–6 It is
thus crucial to ensure improved glycemic control even
in patients with renal impairment.
Renal impairment may often affect the pharmaco-
kinetic parameters of hypoglycemic agents, and their
efﬁcacy and safety could be inﬂuenced by its severity.
The Kidney Disease Improving Global Outcomes guide-
lines7 recently recommended speciﬁc restrictions on
some drug classes; sulfonylureas that are mainly
excreted via the renal route should be avoided in
patients with renal impairment, and metformin use
should be carefully monitored in patients withJanuary 2016estimated glomerular ﬁltration rate (eGFR) Z30 to
o45 mL/min/1.73 m2. Even in Japan, metformin,
except for Metgluco® (Sumitomo Dainippon Pharma
Co. Ltd., Osaka, Japan) is contraindicated in patients
with renal impairment.8,9 Thus, there remains a signiﬁ-
cant unmet need for novel therapeutic options that are
safe and effective in patients with renal impairment.
Luseogliﬂozin, an oral sodium glucose cotransporter
2 (SGLT2) inhibitor discovered and developed by
Taisho Pharmaceuticals Co. Ltd. (Takada, Tokyo,
Japan),10,11 received its ﬁrst global approval in Japan
in March 2014 for the treatment of T2DM, both as
monotherapy and in combination with other oral
hypoglycemic agents (OHAs). Its clinically approved
dosage (2.5 mg/d) for T2DM treatment is the lowest
among the SGLT2 inhibitors currently available world-
wide. Because its mechanism of action is independent
of insulin secretion,12 the risk of hypoglycemia is low.
In Phase II and III studies, luseogliﬂozin was safe and
efﬁcacious in the Japanese population with T2DM,
with signiﬁcant reductions observed in glycated
hemoglobin (HbA1c), body weight, and blood
pressure.13–15 Sustained efﬁcacy and long-term safety
were conﬁrmed in 52-week studies.16,17
Patients with renal impairment in general metab-
olize and excrete drugs differently from patients with
normal renal function. In addition, the pharmacody-
namic parameters of SGLT2 inhibitors could be
inﬂuenced by renal function because the active sites
for these agents are in the renal proximal tubule.12
Urinary glucose excretion (UGE) caused by SGLT2
inhibitors decreases with declining eGFR; similar
results have been reported with other SGLT2
inhibitors.18–22 However, this drug class could be
considered a treatment option in the renal impair-
ment population if shown to be effective and well
tolerated because the number of OHAs available for
use in patients with renal impairment is small. Thus,
it is crucial to investigate the inﬂuence of renal
function on the efﬁcacy and safety of luseogliﬂozin
as well as to assess its risk–beneﬁt proﬁle in patients
with renal impairment. Results could provide prac-
tical guidance for luseogliﬂozin use in clinical prac-
tice. Here, we report the results of a 52-week Phase
III study (Study 1) assessing the efﬁcacy and safety
of luseogliﬂozin in Japanese patients with T2DM
with moderate renal impairment. We also present the
results of a pooled analysis (Study 2) of four 52-week
Phase III studies to investigate the inﬂuence of67
Clinical Therapeuticsvarying degrees of renal function on the efﬁcacy and
safety of luseogliﬂozin.PATIENTS AND METHODS
Study 1 (TS071-03-4): A 52-Week Study in
Patients with Moderate Renal Impairment
Study design
The 52-week study consisted of 2 phases: an initial
24-week double-blind phase followed by an open-
label phase. In the initial phase, patients were random-
ized 2:1 to either 2.5 mg/d luseogliﬂozin or placebo.
After 24 weeks, in the open-label phase, 2.5 or 5 mg/d
luseogliﬂozin was administered to all patients for 28
weeks, regardless of their assigned treatment in the
initial double-blind phase.
This Phase III study (ID: JapicCTI-111543) was
approved by the institutional review board and was
conducted in accordance with the Good Clinical
Practice guidelines, International Conference on Har-
monization guidelines, and the Declaration of Hel-
sinki. All patients provided written informed consent.Patient population
Japanese patients with T2DM with eGFR Z30 to
o60 mL/min/1.73 m2 at Weeks 4 or 2, who were
receiving diet/exercise therapy only or were being
treated with 1 or 2 OHAs at a ﬁxed dose for 48
weeks before study entry (Week 4) were eligible.
Patients with kidney disease accompanied with severe
proteinuria, those with a history of dialysis within 1
year of study entry, and those at risk of developing
ESRD before study completion were excluded. Details
of the election and exclusion criteria are described in
the Supplemental Patients and Methods (see the online
version at http://dx.doi.org/10.1016/j.clinthera.2015.
10.025).Assessment and statistical analysis
In the initial double-blind phase, luseogliﬂozin was
assessed for its efﬁcacy and safety compared with
placebo. Furthermore, efﬁcacy and safety of 52-week
treatment with luseogliﬂozin was evaluated in patients
allocated to luseogliﬂozin in the initial phase. Details
of the assessment and statistical analysis are described
in the Supplemental Patients and Methods (see the
online version at http://dx.doi.org/10.1016/j.clinthera.
2015.10.025).68Study 2: Pooled Analysis
Study design
The pooled analysis consisted of four 52-week,
multicenter, Phase III studies of 2.5 mg/d luseogliﬂozin
(or 5 mg/d after Week 24) in Japanese patients with
T2DM, conducted between May 2011 and October
2012: a combination study with luseogliﬂozin and
glimepiride (TS071-03-1, JapicCTI-111507),16 a
combination study with luseogliﬂozin and another
OHA (ie, biguanide, dipeptidyl peptidase-4 inhibitor,
thiazolidinedione, glinide, or α-glucosidase inhibitor)
(TS071-03-2, JapicCTI-111508),16 a monotherapy
study with luseogliﬂozin (TS071-03-3, JapicCTI-
111509),17 and the present study of luseogliﬂozin in
patients with moderate renal impairment (Study 1)
(TS071-03-4, JapicCTI-111543) (Table I). TS071-03-2
and TS071-03-3 were open-label, 52-week studies,
whereas TS071-03-1 and TS071-03-4 consisted of 2
phases: an initial 24-week placebo-controlled, random-
ized, double-blind, parallel-group comparative phase,
followed by a 28-week open-label phase in which all
patients were given luseogliﬂozin. The pooled analysis
excluded all patients in TS071-03-1 and TS071-03-4
who had received placebo in the initial double-blind
phase (Supplemental Figure S1 in the online version at
http://dx.doi.org/10.1016/j.clinthera.2015.10.025).
All studies were designed in line with the Japa-
nese Guidelines for the Clinical Evaluation of OHAs
and Its Long-Term Treatment and were conducted
with the approval of the ethics committee of each
participating study site and in accordance with the
Declaration of Helsinki and in compliance with
Good Clinical Practice and all applicable regulatory
requirements.
Patient population
Inclusion criteria for patients with T2DM in the
pooled analysis were age Z20 years, HbA1c
Z6.9% to r10.5%, and 48 weeks of regular diet
therapy before study entry. T2DM diagnosis was
based on the Japan Diabetes Society diagnostic
criteria. Exclusion criteria were eGFR o45 mL/
min/1.73 m2 (except Study 1, which included those
with eGFR Z30 to o60 mL/min/1.73 m2), blood
pressure (systolic blood pressure [SBP]/diastolic
blood pressure4170/100 mm Hg, insulin treatment
within 8 weeks before study entry, history of
genitourinary infection, dysuria, or clinically appa-
rent hepatic disorder(s).Volume 38 Number 1
Table I. Studies included in the pooled analysis (Study 2).
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Clinical TherapeuticsInterventions
Luseogliﬂozin at a dosage of 2.5 mg/d was orally
administered to all patients before breakfast for 52
weeks, which could be increased to 5 mg/d after Week
24 in patients with HbA1c Z7.4%, both at Week 16
and Week 20. All patients were receiving diet therapy
to ensure consistent caloric intake during the entire
study period (Weeks –4 to 52). In addition, all patients
were prohibited from taking additional insulin prep-
arations, corticosteroids (except for topical use), or
OHAs other than those coadministered as speciﬁed in
each study protocol. As a rule, the dosages of any
coadministered OHAs were not allowed to be modi-
ﬁed during the entire study period. Patients were
allowed to remain on any lipid-lowering, antihyper-
tensive, or diuretic agents that they had received
before study initiation, whereas they were not allowed
to change their drugs or their daily dose during the
entire study period.
Assessment
The pooled analysis evaluated changes in HbA1c,
fasting plasma glucose (FPG), and body weight as
efﬁcacy variables. Other efﬁcacy variables included
changes in blood pressure and lipid proﬁle. The safety
analyses included the incidence of adverse events
(AEs) and changes in laboratory parameters and vital
signs. During the treatment period, patients visited the
study site at Weeks 0, 2, 4, and every 4 weeks
thereafter until Week 52. All AEs were assessed for
their causal relationship to the study drug as well as
for severity (mild, moderate, or severe).
Statistical Analysis
For the pooled analysis, the efﬁcacy analysis and
the safety analysis included the full analysis set (FAS)
and the safety analysis set (SAS) of each study,
respectively. The FAS/SAS included all patients who
received at least 1 dose of the study drug and for
whom efﬁcacy/safety variables, respectively, were
observed and measured at least once after receiving
the study drug, respectively. Among these popula-
tions, patients who had been randomized to placebo
in the FAS and SAS (in TS071-03-1 and TS071-03-4
studies) and those with baseline eGFR o30 mL/min/
1.73 m2 were excluded. The resulting population was
deﬁned as the pooled analysis set (Supplemental
Figure S1 in the online version at http://dx.doi.org/
10.1016/j.clinthera.2015.10.025).70Patients were stratiﬁed by baseline eGFR into 3
groups: normal renal function (baseline eGFR Z90
mL/min/1.73 m2), mild renal impairment (baseline
eGFR Z60 to o90 mL/min/1.73 m2), and moderate
renal impairment (baseline eGFR Z30 to o60
mL/min/1.73 m2). Patients with moderate renal im-
pairment were further divided into mild-moderate
(baseline eGFR Z45 to o60 mL/min/1.73 m2) and
moderate-severe (baseline eGFR Z30 to o45
mL/min/1.73 m2) renal impairment. eGFR values were
calculated using the equations for eGFR developed by
the Japanese Society of Nephrology for the Japanese
population (males, 194  serum creatinine1.094 
age0.287; females, 194  serum creatinine1.094 
age0.287  0.739).23 All HbA1c values measured
in Japan Diabetes Society units were converted to
their corresponding National Glycohemoglobin
Standardization Program units using the validated
equation (HbA1c [National Glycohemoglobin Stan-
dardization Program] [%] ¼ 1.02  Japan Dia-
betes Society [%] þ 0.25%),24 to allow global
comparisons.
Basic statistics for each efﬁcacy or safety variable
were calculated at each visit, and intragroup mean
changes from baseline for each variable were eval-
uated by the 1-sample t test (missing or unacceptable
data were not imputed). Between-group comparisons
of the changes in HbA1c and FPG were compared
using ANCOVA with their baseline values as cova-
riates. Other efﬁcacy variables were assessed using
ANOVA (unrestricted least signiﬁcant difference
method). The relationship between baseline eGFR
and the degree of change in HbA1c at Week 52,
as well as between baseline HbA1c and the degree
of change in HbA1c, was evaluated by regression
analysis, and the coefﬁcient of determination was
calculated.
In addition, subgroup analyses were conducted
based on baseline HbA1c, eGFR, and SBP. For all
eGFR groups, changes in HbA1c were evaluated in
subgroups with baseline HbA1c o7%, Z7 to o8%,
Z8 to o9%, and Z9%. Changes in SBP were also
evaluated in subgroups with baseline SBP o130 and
Z130 mm Hg. For patients with normal renal
function, changes in eGFR were evaluated in sub-
groups with baseline eGFR Z90 to o100 mL/min/
1.73 m2, Z100 to o110 mL/min/1.73 m2, Z110 to
o120 mL/min/1.73 m2, and Z120 mL/min/1.73 m2.
All tests were conducted with a 2-sided alpha level ofVolume 38 Number 1
M. Haneda et al.0.05. All analyses were conducted using SAS version
9.2 (SAS Institute Inc, Cary, North Carolina).
RESULTS
Study 1 (TS071-03-4): A 52-Week Study in
Patients with Moderate Renal Impairment
Demographic and baseline characteristics
Of the total 145 patients in Study 1, 95 were
randomized to 2.5 mg luseogliﬂozin and 50 to placebo
in the 24-week double-blind phase (Supplemental Figure
S2 in the online version at http://dx.doi.org/10.1016/
j.clinthera.2015.10.025). The demographic and baseline
characteristics of patients were balanced between both
groups. The mean baseline HbA1c was 7.72% in the
luseogliﬂozin group and 7.69% in the placebo group.
The mean baseline eGFR was 52.0 mL/min/1.73 m2 in
the luseogliﬂozin group and 52.4 mL/min/1.73 m2 in the
placebo group, with diabetic nephropathy present in 52
(55.3%) and 26 (52.0%) patients, respectively
(Supplemental Table SI in the online version at http://
dx.doi.org/10.1016/j.clinthera.2015.10.025).
Efficacy outcomes
In the double-blind phase, HbA1c, FPG, and body
weight decreased signiﬁcantly at Week 24 with luseo-
gliﬂozin treatment compared with placebo. The differ-
ences versus placebo in the mean change in these
parameters from baseline were 0.19%, 7.8 mg/dL,
and 1.28 kg, respectively (P ¼ 0.041, P ¼ 0.028,
and P o 0.001 vs placebo, respectively) (Sup-
plemental Table SII in the online version at http://
dx.doi.org/10.1016/j.clinthera.2015.10.025).
From baseline to Week 52, HbA1c decreased
signiﬁcantly from baseline, 0.30% for patients
treated with luseogliﬂozin (P o 0.001 vs baseline).
The mean changes in FPG and body weight were also
signiﬁcantly decreased 14.1 mg/dL and –2.01 kg,
respectively (P o 0.001, for both vs baseline;
Supplemental Table SII in the online version at
http://dx.doi.org/10.1016/j.clinthera.2015.10.025).
Safety outcomes
In the 24-week double-blind phase, patients treated
with luseogliﬂozin had similar incidence of AEs and
adverse drug reactions (67.4% and 18.9%, respec-
tively) compared with the placebo group (62.0% and
10.0%, respectively). The incidence of serious AEs
and AEs leading to discontinuation were similar
between the luseogliﬂozin group (3.2% and 3.2%)January 2016and the placebo group (2.0% and 2.0%). Both groups
showed similar incidence of hypoglycemia (luseogli-
ﬂozin, 3.2%; placebo, 6.0%) (Supplemental Table SIII
in the online version at http://dx.doi.org/10.1016/
j.clinthera.2015.10.025).
In the 52-week period, AEs were observed in
81.1%, adverse drug reactions in 25.3%, and serious
AEs except death were experienced by 9.5% of
patients, while 6.3% of patients withdrew from the
study due to AEs. Most AEs were mild in severity.
Hypoglycemia was observed in 4.2% patients, but
was mild in severity in all cases. Regarding AEs
related to renal function, pollakiuria was most fre-
quently observed (6.3%), followed by increase in
urinary β2-microglobulin (5.3%). No serious AEs
related to renal function were reported. Details of
the safety outcomes are summarized in Supplemental
Table SIII and SIV (the online version at http://dx.doi.
org/10.1016/j.clinthera.2015.10.025).
Study 2: Pooled Analysis
Demographic and baseline characteristics
Table I shows the details of 4 Phase III trials
included in this analysis. Of the 1152 patients in the
4 trials, a total of 1030 patients with T2DM were
included in this analysis (Supplemental Figure S1 in
the online version at http://dx.doi.org/10.1016/
j.clinthera.2015.10.025). Patients were divided into 3
groups based on their baseline eGFR: eGFR Z90 mL/
min/1.73 m2 (normal renal function; n ¼ 275), eGFR
Z60 too90 mL/min/1.73 m2 (mild renal impairment;
n ¼ 598), or eGFR Z30 to o60 mL/min/1.73 m2
(moderate renal impairment; n ¼ 157). Patients with
moderate renal impairment were further divided into
2 groups, with 130 having mild-moderate impairment
(eGFR Z45 to o60 mL/min/1.73 m2) and 27 having
moderate-severe impairment (eGFR Z30 to o45 mL/
min/1.73 m2). Among these groups, the mean HbA1c
ranged from 7.68% to 8.02% (Table II). The
proportion of patients completing the 52-week treat-
ment was similar between groups (89.8%, 92.5%,
and 89.8% completing treatment for the normal renal
function, mild renal impairment, and moderate renal
impairment groups, respectively).
Efficacy outcome
HbA1c signiﬁcantly decreased at Week 52 from
baseline in all eGFR groups. The mean changes in
HbA1c were 0.67% in patients with normal renal71
Table II. Demographic and baseline characteristics for all eGFR groups who received luseogliflozin (Study 2 : pooled analysis)
Normal
Mild
impairment
Moderate
impairment
eGFR Z 90 eGFR Z 60 to o 90 eGFR Z 30 to o 60
Mild-moderate Moderate-severe
eGFR Z 45 to o 60 eGFR Z 30 to o 45
No. of patients at baseline (n ¼ 275) (n ¼ 598) (n ¼ 157) (n ¼ 130) (n ¼ 27)
Age (mean  SD), years 54.0  11.1 61.7  9.3 66.9  8.4 66.5  8.1 69.0  9.7
Male, n (%) 185 (67.3) 416 (69.6) 112 (71.3) 95 (73.1) 17 (63.0)
Duration of diabetes (mean  SD), years* 5.5  5.7 6.3  5.7 9.1  6.9 8.4  5.8 12.5  10.0
Body weight (mean  SD), kg 70.40  14.99 67.85  12.63 65.87  12.38 66.47  12.63 62.99  10.85
BMI (mean  SD), kg/m2 26.06  4.66 25.54  3.82 25.07  3.56 25.16  3.49 24.64  3.90
HbA1c (mean  SD), % 8.02  0.86 7.79  0.73 7.71  0.71 7.68  0.71 7.83  0.71
o 7%, n (%) 13 (4.7) 22 (3.7) 8 (5.1) 7 (5.4) 1 (3.7)
Z 7% to o 8%, n (%) 145 (52.7) 389 (65.1) 107 (68.2) 90 (69.2) 17 (63.0)
Z 8% to o 9%, n (%) 71 (25.8) 135 (22.6) 29 (18.5) 23 (17.7) 6 (22.2)
Z 9%, n (%) 46 (16.7) 52 (8.7) 13 (8.3) 10 (7.7) 3 (11.1)
FPG (mean  SD), mg/dL 151.1  30.3 143.2  26.6 138.1  30.0 137.6  29.7 140.9  31.9
Glycoalbumin (mean  SD), % 20.45  3.30 20.33  3.32 20.38  3.44 20.13  3.42 21.54  3.36
Fasting insulin (mean  SD), μU/mL 7.70  5.27 7.47  5.34 7.95  5.78 8.35  6.09 6.04  3.38
Fasting CPR (mean  SD), ng/mL 1.31  0.57 1.37  0.60 1.59  0.79 1.57  0.79 1.68  0.84
eGFR (mean  SD), mL/min/1.73 m2 103.52 
12.72
75.63  8.13 51.88  6.64 54.30  3.96 40.19  3.96
Serum creatinine (mean  SD), mg/dL 0.586  0.100 0.754  0.119 1.051  0.189 1.003  0.137 1.282  0.230
Urinary albumin (Cr-corrected)
(mean  SD), mg/g Cr
36.4  65.2 49.5  257.6 172.3  561.9 126.1  513.4 394.8  724.3
SBP (mean  SD), mm Hg 127.9  14.1 127.9  14.7 130.9  15.8 130.7  16.0 131.7  15.0
DBP (mean  SD), mm Hg 77.3  9.9 75.2  10.1 74.9  9.7 74.9  9.9 75.1  8.8
No use of hypoglycemic agents, n (%) 90 (32.7) 178 (29.8) 38 (24.2) 33 (25.4) 5 (18.5)
Concomitant hypoglycemic agents, n (%) 185 (67.3) 420 (70.2) 119 (75.8) 97 (74.6) 22 (81.5)
Metformin, n (%) 42 (15.3) 72 (12.0) 20 (12.7) 17 (13.1) 3 (11.1)
Sulfonylurea, n (%) 44 (16.0) 102 (17.1) 59 (37.6) 46 (35.4) 13 (48.1)
Thiazolidinedione, n (%) 21 (7.6) 69 (11.5) 16 (10.2) 13 (10.0) 3 (11.1)
DPP4 inhibitor, n (%) 32 (11.6) 77 (12.9) 26 (16.6) 18 (13.8) 8 (29.6)
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Table II. (continued).
Normal
Mild
impairment
Moderate
impairment
eGFR Z 90 eGFR Z 60 to o 90 eGFR Z 30 to o 60
Mild-moderate Moderate-severe
eGFR Z 45 to o 60 eGFR Z 30 to o 45
Glinide, n (%) 21 (7.6) 33 (5.5) 11 (7.0) 10 (7.7) 1 (3.7)
GLP1 receptor agonist, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
α-Glucosidase inhibitor, n (%) 25 (9.1) 80 (13.4) 18 (11.5) 12 (9.2) 6 (22.2)
History of hypoglycemic agents use, n (%) 101 (36.7) 213 (35.6) 56 (35.7) 48 (36.9) 8 (29.6)
Concomitant lipid-lowering agents, n (%) 97 (35.3) 309 (51.7) 107 (68.2) 87 (66.9) 20 (74.1)
Concomitant diuretics, n (%) 14 (5.1) 68 (11.4) 29 (18.5) 21 (16.2) 8 (29.6)
Thiazide, n (%) 14 (5.1) 49 (8.2) 23 (14.6) 17 (13.1) 6 (22.2)
Loop diuretic, n (%) 0 (0.0) 7 (1.2) 3 (1.9) 2 (1.5) 1 (3.7)
Concomitant antihypertensive agents, n
(%)
102 (37.1) 314 (52.5) 119 (75.8) 96 (73.8) 23 (85.2)
ARB, n (%) 70 (25.5) 242 (40.5) 91 (58.0) 72 (55.4) 19 (70.4)
ACE inhibitor, n (%) 9 (3.3) 24 (4.0) 13 (8.3) 10 (7.7) 3 (11.1)
Diabetic complications, n (%) 99 (36.0) 202 (33.8) 77 (49.0) 59 (45.4) 18 (66.7)
Diabetic nephropathy, n(%) 55 (20.0) 138 (23.1) 59 (37.6) 44 (33.8) 15 (55.6)
Diabetic neuropathy, n(%) 29 (10.5) 56 (9.4) 23 (14.6) 17 (13.1) 6 (22.2)
Diabetic retinopathy, n (%) 28 (10.2) 55 (9.2) 25 (15.9) 15 (11.5) 10 (37.0)
Other, n (%) 3 (1.1) 5 (0.8) 8 (5.1) 5 (3.8) 3 (11.1)
Non-diabetic complications
Hypertension, n (%) 112 (40.7) 355 (59.4) 125 (79.6) 102 (78.5) 23 (85.2)
Hyperlipidemia, n (%) 192 (69.8) 456 (76.3) 130 (82.8) 105 (80.8) 25 (92.6)
Renal disease, n (%) 19 (6.9) 58 (9.7) 38 (24.2) 30 (23.1) 8 (29.6)
Cardiac disease, n (%) 19 (6.9) 68 (11.4) 36 (22.9) 31 (23.8) 5 (18.5)
Endocrine disease, n (%) 8 (2.9) 14 (2.3) 2 (1.3) 2 (1.5) 0 (0.0)
Hepatobiliary diseases, n (%) 121 (44.0) 238 (39.8) 55 (35.0) 47 (36.2) 8 (29.6)
Gastrointestinal disease, n (%) 68 (24.7) 200 (33.4) 60 (38.2) 48 (36.9) 12 (44.4)
Other, n (%) 224 (81.5) 510 (85.3) 144 (91.7) 119 (91.5) 25 (92.6)
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; BMI ¼ body-mass index; CPR ¼ C-peptide immunoreactivity; Cr ¼ creatinine;
DBP ¼ diastolic blood pressure; DPP4 ¼ dipeptidyl peptidase 4; eGFR ¼ estimated glomerular ﬁltration rate (in mL/min/1.73 m2); FPG ¼ fasting plasma glucose;
GLP-1 ¼ glucagon-like peptide 1; HbA1c ¼ hemoglobin A1c; SBP ¼ systolic blood pressure; SD ¼ standard deviation.
*n ¼ 274 (normal), n ¼ 597 (mild impairment), n ¼ 155 (moderate impairment), n ¼ 129 (mild-moderate impairment), n ¼ 26 (moderate-severe impairment).
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Figure 1. Changes from baseline in (A) HbA1c, (B)
FPG, and (C) body weight at week 52
(Study 2: pooled analysis). HbA1c and
FPG were compared between the groups
using ANCOVA with their baseline values
as covariates. Body weight was compared
between the groups using ANOVA. Data
are presented as means ± 95%CI. *P o
0.05 versus those with normal renal
function. ANCOVA = analysis of covar-
iance; ANOVA = analysis of variance; CI =
confidence interval; eGFR = esti-
mated glomerular filtration rate; FPG =
fasting plasma glucose; HbA1c =
hemoglobin A1c.
Clinical Therapeuticsfunction, 0.55% in patients with mild renal impair-
ment, and 0.32% in patients with moderate renal
impairment (all groups, P o 0.001 vs baseline)
(Figure 1A and Table III). In patients with moderate
renal impairment, HbA1c decreased signiﬁcantly from
baseline in both the mild-moderate and moderate-
severe subgroups (0.32% for both; P o 0.001 and
P ¼ 0.005, respectively). HbA1c was decreased
signiﬁcantly as early as the ﬁrst scheduled visit at
Week 2 and maintained throughout the study period
until Week 52 in all 3 eGFR groups (Supplemental
Figure S3A in the online version at http://dx.doi.org/
10.1016/j.clinthera.2015.10.025).
FPG was decreased signiﬁcantly at week 52 com-
pared with baseline in all eGFR groups, with mean
changes of 23.8, 16.9, and 14.1 mg/dL, respec-
tively, in patients with normal renal function, mild
renal impairment, and moderate renal impairment
(all groups, P o 0.001 vs baseline) (Figure 1B and
Table III). Furthermore, FPG levels were signiﬁcantly
decreased by 14.5 and 12.0 mg/dL from baseline
in the mild-moderate and moderate-severe renal impair-
ment subgroups, (Po 0.001 and P¼ 0.008, respectively)
(Supplemental Figure S3B in the online version at http://
dx.doi.org/10.1016/j.clinthera.2015.10.025).
Body weight was signiﬁcantly decreased at Week
52 in all eGFR groups, with mean changes of 2.68,
2.52, and 2.03 kg, respectively, for normal, mild,
and moderate groups (all groups, P o 0.001 vs
baseline) (Figure 1C and Table III). In the subgroup
analysis, the mean changes in body weight were
2.03 and 2.05 kg in patients with mild-moderate
and moderate-severe renal impairment, respectively,
showing a signiﬁcant decrease from baseline (P o
0.001 for both). Body weight rapidly decreased until
Week 12, with a gradual decrease thereafter
(Supplemental Figure S3C in the online version at
http://dx.doi.org/10.1016/j.clinthera.2015.10.025).
In the between-group comparisons, the change in
HbA1c at Week 52 was signiﬁcantly lower in patients
with moderate renal impairment than in those with
normal renal function, but no signiﬁcant difference
was observed between patients with normal renal
function and mild renal impairment. No signiﬁcant
differences were observed in FPG between groups at
Week 52. Again, the changes in body weight at Week
52 were signiﬁcantly different between patients with
normal renal function and moderate renal impairment
but not between patients with normal renal function74and mild renal impairment. The HbA1c- and body
weight-reducing efﬁcacy of luseogliﬂozin, as assessed
by mean changes in HbA1c and body weight, wasVolume 38 Number 1
Table III. Change in efficacy parameters from baseline to Week 52 for all eGFR groups who received luseogliflozin (Study 2: pooled analysis).*
Normal
eGFR Z90
mL/min/1.73 m2
Mild impairment
eGFR Z60 to o90
mL/min/1.73 m2
Moderate impairment
eGFR Z30 to o60
mL/min/1.73 m2
Mild-moderate
eGFR Z45 to o60
mL/min/1.73 m2
Moderate-severe
eGFR Z30 to o45
mL/min/1.73 m2
No. of patients at
baseline
275 598 157 130 27
No. of patients at Week
52
247 553 141 119 22
HbA1c, %
Baseline 8.02 (0.86) 7.79 (0.73) 7.71 (0.71) 7.68 (0.71) 7.83 (0.71)
Change at Week 52 0.67 (0.77 to 0.58)† 0.55 (0.60 to 0.50)† 0.32 (0.41 to 0.22)† 0.32 (0.42 to 0.21)† 0.32 (0.54 to 0.11)||
FPG, mg/dL
Baseline 151.1 (30.3) 143.2 (26.6) 138.1 (30.0) 137.6 (29.7) 140.9 (31.9)
Change at Week 52 23.8 (27.0 to 20.5)† 16.9 (18.8 to 15.1)† 14.1 (17.9 to 10.4)† 14.5 (18.7 to 10.3)† 12.0 (20.5 to 3.5)||
Body weight, kg
Baseline 70.40 (14.99) 67.85 (12.63) 65.87 (12.38) 66.47 (12.63) 62.99 (10.85)
Change at Week 52 2.68 (3.00 to 2.36)† 2.52 (2.70 to 2.33)† 2.03 (2.37 to 1.70)† 2.03 (2.41 to 1.66)† 2.05 (2.88 to 1.21)†
Change at Week 52, % 3.78 (4.21 to 3.35)† 3.70 (3.96 to 3.44)† 3.08 (3.61 to 2.55)† 3.06 (3.65 to 2.48)† 3.18 (4.50 to 1.85)†
Glycoalbumin, %
Baseline 20.45 (3.30) 20.33 (3.32) 20.38 (3.44) 20.13 (3.42) 21.54 (3.36)
Change at Week 52 2.84 (3.11 to 2.57)† 2.32 (2.50 to 2.14)† 1.59 (1.92 to 1.25)† 1.69 (2.05 to 1.32)† 1.05 (1.89 to 0.21)||
Fasting insulin,
μU/mL
Baseline 7.70 (5.27) 7.47 (5.34) 7.95 (5.78) 8.35 (6.09) 6.04 (3.38)
Change at Week 52 1.98 (2.42 to 1.53)† 1.71 (1.95 to 1.48)† 1.86 (2.42 to 1.29)† 1.99 (2.63 to 1.36)† 1.11 (2.18 to 0.04)||
Fasting CPR, ng/mL
Baseline 1.31 (0.57) 1.37 (0.60) 1.59 (0.79) 1.57 (0.79) 1.68 (0.84)
Change at Week 52 0.26 (0.30 to 0.21)† 0.23 (0.26 to 0.20)† 0.22 (0.29 to 0.15)† 0.23 (0.30 to 0.16)† 0.16 (0.42 to 0.09)
CPI
Baseline 0.89 (0.41) 0.98 (0.45) 1.16 (0.53) 1.15 (0.51) 1.21 (0.63)
Change at Week 52 0.05 (0.09 to 0.02)|| 0.07 (0.09 to 0.05)† 0.05 (0.11 to 0.00)‡ 0.06 (0.12 to 0.00)§ 0.03 (0.19 to 0.13)
SBP, mm Hg
Baseline 127.9 (14.1) 127.9 (14.7) 130.9 (15.8) 130.7 (16.0) 131.7 (15.0)
Change at Week 52 4.7 (6.3 to 3.1)† 4.4 (5.5 to 3.3)† 5.5 (7.8 to 3.3)† 6.1 (8.5 to 3.7)† 2.4 (8.8 to 4.0)
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Table III. (continued).
Normal
eGFR Z90
mL/min/1.73 m2
Mild impairment
eGFR Z60 to o90
mL/min/1.73 m2
Moderate impairment
eGFR Z30 to o60
mL/min/1.73 m2
Mild-moderate
eGFR Z45 to o60
mL/min/1.73 m2
Moderate-severe
eGFR Z30 to o45
mL/min/1.73 m2
DBP, mm Hg
Baseline 77.3 (9.9) 75.2 (10.1) 74.9 (9.7) 74.9 (9.9) 75.1 (8.8)
Change at Week 52 2.4 (3.4 to 1.3)† 2.6 (3.4 to 1.9)† 3.1 (4.6 to 1.6)† 3.1 (4.7 to 1.5)† 2.7 (6.9 to 1.4)
Triglyceride, mg/dL
Baseline 144.5 (108.8) 139.9 (92.0) 151.6 (111.0) 150.4 (113.2) 157.1 (101.9)
Change at Week 52 24.2 (37.7 to 10.7)† 17.0 (23.6 to 10.3)† 5.6 (21.6 to 10.4) 3.9 (22.5 to 14.6) 14.4 (37.4 to 8.6)
HDL-C, mg/dL
Baseline 58.5 (15.5) 56.4 (14.8) 57.0 (14.7) 57.1 (14.2) 56.6 (17.0)
Change at Week 52 4.7 (3.6 to 5.8)† 5.7 (5.0 to 6.4)† 3.6 (2.2 to 5.0)† 4.0 (2.5 to 5.4)† 1.5 (3.0 to 6.0)
LDL-C, mg/dL
Baseline 117.7 (28.1) 117.0 (28.6) 114.0 (30.2) 114.0 (31.0) 113.8 (26.5)
Change at Week 52 2.0 (1.0 to 4.9) 1.8 (0.1 to 3.5)|| 1.0 (4.2 to 2.2) 1.2 (4.9 to 2.5) 0.1 (5.7 to 5.9)
non-HDL-C, mg/dL
Baseline 139.1 (33.4) 137.9 (32.7) 136.0 (34.5) 135.9 (35.5) 136.5 (29.5)
Change at Week 52 3.6 (7.0 to 0.3)|| 2.8 (4.6 to 0.9)|| 3.8 (7.5 to 0.1)|| 3.8 (7.9 to 0.4) 3.9 (12.4 to 4.6)
LDL-C/HDL-C
Baseline 2.15 (0.76) 2.22 (0.81) 2.13 (0.78) 2.12 (0.80) 2.17 (0.71)
Change at Week 52 0.13 (0.19 to 0.08)† 0.15 (0.19 to 0.12)† 0.11 (0.18 to 0.04)|| 0.12 (0.20 to 0.04)|| 0.07 (0.24 to 0.10)
Adiponectin, μg/mL
Baseline 6.85 (4.03) 7.97 (5.54) 9.26 (5.63) 8.63 (5.19) 12.31 (6.70)
Change at Week 52 0.80 (0.61 to 1.00)† 0.99 (0.80 to 1.17)† 0.81 (0.52 to 1.10)† 0.86 (0.59 to 1.12)† 0.58 (0.73 to 1.88)
Leptin, ng/mL
Baseline 7.89 (5.93) 7.80 (5.53) 8.56 (6.88) 8.40 (5.68) 9.37 (11.08)
Change at Week 52 1.12 (1.46 to 0.79)† 0.83 (1.08 to 0.59) † 0.64 (1.14 to 0.13)|| 0.81 (1.35 to 0.28)|| 0.32 (1.20 to 1.83)
CPI ¼ C-peptide index; CPR ¼ C-peptide immunoreactivity; DBP ¼ diastolic blood pressure; eGFR ¼ estimated glomerular ﬁltration rate; FPG ¼ fasting plasma
glucose; HbA1c ¼ hemoglobin A1c; HDL-C ¼ high-density lipoprotein cholesterol; LDL-C ¼ low-density lipoprotein cholesterol; SBP ¼ systolic blood pressure.
*Data are presented as mean (SD) for baseline values and as mean (95% CI) for changes at Week 52.
†P o 0.001 versus baseline, based on 1-sample t test.
‡n ¼ 140.
§n ¼ 118.
||P o 0.05 versus baseline, based on 1-sample t test.
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M. Haneda et al.diminished by 47.2% and 76.0%, respectively, in
patients with moderate renal impairment, compared
with normal renal function.
Relationship between the degree of change in HbA1c,
baseline eGFR, and baseline HbA1c
A scatter plot showed a weak correlation for the
greater decrease in HbA1c at Week 52 seen with
higher baseline eGFR values (r2 ¼ 0.0361; Po 0.001)
(Figure 2). In addition, it indicated an apparent
negative correlation between the degree of change in
HbA1c at Week 52 and the baseline HbA1c level
(r2 ¼ 0.455; P o 0.001), demonstrating that the
higher the baseline HbA1c, the greater the decrease in
HbA1c across all eGFR groups.4
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Figure 2. Correlation between changes in HbA1c
and baseline values (Study 2: pooled
analysis). (A) Correlation between
changes in HbA1c at week 52 and base-
line HbA1c values. (B) Correlation be-
tween changes in HbA1c at week 52 and
baseline eGFR values. eGFR ¼ estimated
glomerular filtration rate; HbA1c ¼
hemoglobin A1c.
January 2016Given that the change in HbA1c was shown to vary
depending on the baseline HbA1c value, a subgroup
analysis based on baseline HbA1c (o7%, Z7% to
o8%, Z8% to o 9%, and Z9%) was conducted,
which conﬁrmed that the higher the baseline HbA1c,
the greater the decrease in HbA1c across all eGFR
groups (Supplemental Figure S4 in the online version
at http://dx.doi.org/10.1016/j.clinthera.2015.10.025). In
patients with higher baseline HbA1c values (ie, baseline
HbA1c values Z8% to o9%), the HbA1c changes
were 0.89, 0.82, and 0.62%, respectively, for those
with normal renal function, mild renal impairment, and
moderate renal impairment.Other efficacy outcomes
At Week 52, glycoalbumin, fasting insulin, and
fasting C-peptide immunoreactivity levels were signiﬁ-
cantly decreased from baseline in all eGFR groups,
with the exception of fasting C-peptide immunoreac-
tivity levels in patients with moderate-severe renal
impairment. C-peptide index was signiﬁcantly de-
creased only in patients with normal renal function
and mild renal impairment (Table III).
Both SBP and diastolic blood pressure were
signiﬁcantly decreased at Week 52 from baseline
in all eGFR groups with a similar decrease noted for
both variables (Table III). These parameters were
also decreased in patients with mild-moderate and
moderate-severe renal impairment but only signiﬁ-
cant in patients with mild-moderate renal impair-
ment (P o 0.001). A subgroup analysis based on
baseline SBP showed that the degree of SBP decrease
in patients with SBP Z130 mm Hg was also similar
across all eGFR groups, with the changes at Week
52 being 9.5, 10.6, and 9.1 mm Hg in patients
with normal renal function, mild renal impairment,
and moderate renal impairment, respectively, each
demonstrating a signiﬁcant decrease from baseline
(all groups, P o 0.001) (Supplemental Table SV in
the online version at http://dx.doi.org/10.1016/
j.clinthera.2015.10.025).
Triglyceride levels, non-HDL cholesterol levels,
LDL to HDL cholesterol ratio, and leptin levels
decreased, except for leptin in patients with moderate-
severe impairment, whereas HDL cholesterol and
adiponectin levels increased in all eGFR groups. No
appreciable change in LDL cholesterol level was
observed in any eGFR group (Table III).77
Clinical TherapeuticsSafety outcome
AEs observed during 52 weeks of treatment with
luseogliﬂozin are summarized in Table IV. The
incidence of AEs was similar across all eGFR
groups, including those with mild-moderate and
moderate-severe renal impairment. The majority of
the AEs were of mild severity. The incidence of serious
AEs and AEs leading to discontinuation was similar
among patients with normal renal function, mild renal
impairment, and moderate renal impairment, but
tended to be higher in those with moderate-severe
renal impairment. Two deaths were reported in
patients with mild-moderate renal impairment, both
were unrelated to the study drug as judged by the
study investigators.
The incidence of hypoglycemia was similar across
all eGFR groups, with the majority being mild in
severity and no severe or serious hypoglycemia noted.
The patients who received the combination of luseo-
gliﬂozin and sulfonylurea had a tendency toward a
higher incidence of hypoglycemia in all eGFR groups.
The incidence of AEs related to renal function was
higher in patients with moderate renal impairment
than in patients with normal renal function and mild
renal impairment. Of AEs related to renal function in
all eGFR groups, more than two-thirds were labora-
tory abnormalities, with the most frequent being
increase in urinary β2-microglobulin. Increase in
blood creatinine were noted in 1 patient with mild
renal impairment and in 2 patients with moderate-
severe renal impairment, all of which were mild in
severity and judged to be unrelated to the study drug.
No AEs suggestive of clearly worsening renal function
were noted in any group.
The incidence of AEs related to volume depletion or
AEs related to cardiovascular disorders were similar
among all eGFR groups; however, the incidence was
relatively higher in patients with moderate-severe renal
impairment. A similar incidence of urinary or genital
infections was seen across all eGFR groups. The incidence
of AEs related to bone metabolism was similar across all
eGFR groups, and none of the bone fracture reported
was considered to be related to the study drug.
Laboratory parameters
eGFR signiﬁcantly decreased from baseline within
the initial 2 weeks of treatment with luseogliﬂozin but
increased immediately thereafter and remained above
baseline levels in all eGFR groups (Figure 3). eGFR78decreased and returned to baseline levels in patients
with mild and moderate renal impairment after Week
36, whereas eGFR decreased and remained below
baseline levels in patients with normal renal function.
eGFR was comparable at Week 52 to baseline in
patients with mild and moderate renal impairment but
had signiﬁcantly decreased in those with normal renal
function. Given the decrease in eGFR among patients
with normal renal function, a subgroup analysis by
baseline eGFR showed that the changes in eGFR at
Week 52 were 0.56, 2.46, 3.15, and 6.92 mL/
min/1.73 m2 among patients with baseline eGFRZ90
to o100 mL/min/1.73 m2, Z100 to o110 mL/min/
1.73 m2, Z110 to o120 mL/min/1.73 m2, and eGFR
Z120 mL/min/1.73 m2, respectively thus showing a
signiﬁcant decrease from baseline in those with eGFR
Z100 to o110 mL/min/1.73 m2 (P ¼ 0.030) and
Z120 mL/min/1.73 m2 (P ¼ 0.001) (Supplemental
Figure S5 in the online version at http://dx.doi.org/10.
1016/j.clinthera.2015.10.025).
Serum creatinine levels were hardly changed in any
eGFR group; however, signiﬁcant change was observed
only in patients with normal renal function. Urinary
β2-microglobulin signiﬁcantly increased in all eGFR
groups; this elevation was observed especially in
patients with moderate renal impairment, but no
signiﬁcant change was shown in those with moderate-
severe renal impairment. Most patients with high
urinary β2-microglobulin levels were asymptomatic.
Although urinary albumin (creatinine (Cr)-corrected)
was not signiﬁcantly different at Week 52, it tended to
decrease especially in those with moderate renal impair-
ment whose baseline value was higher (Table V).
Additionally, there was a signiﬁcant increase in
hematocrit (Ht), blood urea nitrogen (BUN), and BUN
to creatinine ratio from baseline in all eGFR groups,
except BUN and BUN to creatinine ratio in patients
with moderate-severe renal impairment (Table V).
Alanine aminotransferase, aspartate aminotransferase,
and uric acid were signiﬁcantly decreased in all eGFR
groups, except aspartate aminotransferase and uric acid
in moderate-severe group.DISCUSSION
This is the ﬁrst study to evaluate the safety and
efﬁcacy of luseogliﬂozin in Japanese patients with
T2DM with various degrees of renal impairment.
Given that the amount of glucose ﬁltered by theVolume 38 Number 1
Table IV. Adverse events reported during 52 weeks of treatment with luseogliflozin for all eGFR groups (Study 2: pooled analysis).
Normal
eGFR Z90
mL/min/1.73 m2
Mild impairment
eGFR Z60 to o90
mL/min/1.73 m2
Moderate impairment
eGFR Z30 to o60
mL/min/1.73 m2
Mild-moderate
eGFR Z45 to o60
mL/min/1.73 m2
Moderate-severe
eGFR Z30 to o45
mL/min/1.73 m2
No. of patients at baseline n ¼ 275 n ¼ 598 n ¼ 157 n ¼ 130 n ¼ 27
AEs 207 (75.3) 467 (78.1) 124 (79.0) 102 (78.5) 22 (81.5)
Adverse drug reactions 55 (20.0) 104 (17.4) 39 (24.8) 32 (24.6) 7 (25.9)
Deaths* 0 (0.0) 0 (0.0) 2 (1.3) 2 (1.5) 0 (0.0)
Serious AEs† 20 (7.3) 35 (5.9) 13 (8.3) 6 (4.6) 7 (25.9)
AEs leading to
discontinuation
13 (4.7) 26 (4.3) 9 (5.7) 6 (4.6) 3 (11.1)
AEs of special interest
Hypoglycemia‡ 9 (3.3) 22 (3.7) 8 (5.1) 7 (5.4) 1 (3.7)
AEs related to pollakiuria§ 13 (4.7) 10 (1.7) 7 (4.5) 6 (4.6) 1 (3.7)
AEs related to volume
depletion||
3 (1.1) 9 (1.5) 4 (2.5) 1 (0.8) 3 (11.1)
Hypotension¶ 1 (0.4) 4 (0.7) 3 (1.9) 2 (1.5) 1 (3.7)
AEs related to cardiovascular
disorders#
11 (4.0) 30 (5.0) 8 (5.1) 5 (3.8) 3 (11.1)
Urinary tract infection** 13 (4.7) 18 (3.0) 7 (4.5) 5 (3.8) 2 (7.4)
Urinary tract infection
(excluding laboratory
abnormalities)
7 (2.5) 9 (1.5) 5 (3.2) 4 (3.1) 1 (3.7)
Genital infections†† 7 (2.5) 5 (0.8) 2 (1.3) 1 (0.8) 1 (3.7)
AEs related to renal
function‡‡
35 (12.7) 70 (11.7) 33 (21.0) 25 (19.2) 8 (29.6)
Laboratory abnormalities 24 (8.7) 54 (9.0) 23 (14.6) 18 (13.8) 5 (18.5)
Increase in urinary β2-
microglobulin
13 (4.7) 25 (4.2) 15 (9.6) 12 (9.2) 3 (11.1)
Urinary albumin
positive
3 (1.1) 17 (2.8) 5 (3.2) 5 (3.8) 0 (0.0)
(continued)
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Table IV. (continued).
Normal
eGFR Z90
mL/min/1.73 m2
Mild impairment
eGFR Z60 to o90
mL/min/1.73 m2
Moderate impairment
eGFR Z30 to o60
mL/min/1.73 m2
Mild-moderate
eGFR Z45 to o60
mL/min/1.73 m2
Moderate-severe
eGFR Z30 to o45
mL/min/1.73 m2
Increase in blood
creatinine
0 (0.0) 1 (0.2) 2 (1.3) 0 (0.0) 2 (7.4)
Decrease in GFR 0 (0.0) 1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0)
Increase in blood urea 0 (0.0) 1 (0.2) 2 (1.3) 0 (0.0) 2 (7.4)
Urinary protein positive 4 (1.5) 1 (0.2) 4 (2.5) 3 (2.3) 1 (3.7)
Increase in cystatin C 0 (0.0) 1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0)
AEs related to bone
metabolism§§
3 (1.1) 18 (3.0) 1 (0.6) 1 (0.8) 0 (0.0)
AEs related to increase in
ketone bodies||||
11 (4.0) 17 (2.8) 4 (2.5) 4 (3.1) 0 (0.0)
AEs related to skin
disorders¶¶
25 (9.1) 39 (6.5) 13 (8.3) 10 (7.7) 3 (11.1)
AE ¼ adverse event; eGFR ¼ estimate glomerular ﬁltration rate (in mL/min/1.73 m2). Data are presented as n (%).
*Acute myocardial infarction, pancreatic cancer.
†Including death.
‡Decrease in blood glucose, hypoglycemia, and hypoglycemia unawareness.
§Increase in urine volume and pollakiuria.
||Thirst, decrease in blood potassium, increase in blood urea, uric acid, hematocrit, hemoglobin and red blood cell count, and dehydration.
¶Decrease in blood pressure, hypotension, and orthostatic hypotension.
#Including preferred terms related to cardiovascular disorders (eg, cardiac disorder, ophthalmopathy, edema, vital abnormalities, and nervous system disorder).
**Including laboratory abnormalities (ie, urinary white blood cell positive, bacterial test positive, and fungal test positive ) and others (eg, cystitis, pyelonephritis,
urinary tract infection, and bacterial cystitis).
††Candida balanitis, genital candidiasis, genital herpes, vulvitis, vulvovaginal candidiasis, bacterial vaginosis, and prostatitis.
‡‡Including laboratory abnormalities and others (ie, dysuria, nephrolithiasis, neurogenic bladder, pollakiuria, renal cyst, urge incontinence, urinary retention, renal
cyst hemorrhage, and stress urinary incontinence).
§§Bone fracture, increase in blood parathyroid hormone, and increase in blood phosphate level.
||||Increase in free fatty acids, increase in blood ketone bodies, urinary ketone body positive, ketosis, and metabolic acidosis.
¶¶Dermatitis, dermatitis allergic, dermatitis contact, drug eruption, eczema, asteatotic eczema, eczema nummular, erythema, heat rash, prurigo, rash, urticaria, and
seborrheic dermatitis.
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Figure 3. (A) Changes in eGFR over time during
52 weeks among the eGFR groups, and
(B) changes in eGFR at week 52 from
baseline among the eGFR groups
(Study 2: pooled analysis). Data are
presented as means ± 95%CI and
changes from baseline. **Po0.001
versus baseline based on 1-sample t
test. CI = confidence interval; eGFR =
estimated glomerular filtration rate.
M. Haneda et al.kidney is determined by the GFR in SGLT2 inhibition,
it is crucial to assess how renal impairment may affect
the efﬁcacy and safety of SGLT2 inhibitors, including
luseogliﬂozin, when considering their use in patients
with T2DM who may also have renal impairment.
According to the results of earlier pharmacologic
studies of SGLT2 inhibitors in patients with varying
degrees of renal function,18–22 the amount of UGE
becomes smaller with declining eGFR. Therefore, the
long-term efﬁcacy and safety of luseogliﬂozin required
conﬁrmation in patients with renal impairment. In
addition, an assessment of luseogliﬂozin’s risks and
beneﬁts relative to renal function was also important.
In Study 1, we found that a 52-week treatment
with luseogliﬂozin decreased HbA1c and was well
tolerated in patients with T2DM with moderate renalJanuary 2016impairment. In Study 2, in which we evaluated the
inﬂuence of renal function on the efﬁcacy and safety of
luseogliﬂozin in more than 1000 Japanese patients
with normal to moderately impaired renal function,
HbA1c, FPG, and body weight decreased signiﬁcantly
from baseline to Week 52 in all groups, regardless of
renal function. In between-group comparisons, the
decreases in HbA1c and body weight were signiﬁ-
cantly smaller in patients with moderate renal impair-
ment (eGFR Z30 to o60 mL/min/1.73 m2) than
in those with normal renal function (eGFR
Z90 mL/min/1.73 m2). This was not unexpected,
because the amount of UGE is correlated with eGFR,
suggesting that the lesser the increase in UGE, the
lesser the glucose-lowering or body weight reduction
with luseogliﬂozin. In this regard, our results are
consistent with previous pharmacologic studies,18–22
showing a similar trend with Phase III studies of other
SGLT2 inhibitors in patients with renal impairment,
especially in regard to the HbA1c results.25–28 Re-
garding FPG changes, however, no signiﬁcant differ-
ences were observed among the eGFR groups. Because
of the varying baseline FPG levels observed among the
groups, which could have affected the study results,
HbA1c and FPG were compared by using ANCOVA
with their baseline values as covariates.
In agreement with an earlier meta-analysis of
OHAs,29 our analysis also showed that not only a
higher baseline eGFR but also a higher baseline
HbA1c value resulted in a greater decrease in
HbA1c at Week 52 in all eGFR groups. Further-
more, a scatter plot analysis showed that, whereas
both baseline eGFR and HbA1c were negatively
correlated with the decreases in HbA1c at Week 52,
baseline HbA1c had a stronger correlation than
baseline eGFR. The subgroup analysis showed that
higher baseline HbA1c was associated with greater
decrease in HbA1c; this was seen even in patients with
moderate renal impairment. The change in HbA1c at
Week 52 was 0.62% in patients having moderate
renal impairment with baseline HbA1c Z8% to
o9% and 1.27% in those with baseline HbA1c
Z9%, compared with 0.32% in all patients (7.71%
at baseline). These results suggest that luseogliﬂozin
may represent a therapeutic option for patients with
moderate renal impairment whose baseline HbA1c is
relatively high and who are at low risk of developing
AEs.81
Table V. Change in laboratory parameters from baseline at Week 52 for all eGFR groups of patients who received luseogliflozin (Study 2: pooled
analysis).*
Normal
eGFR Z90
mL/min/1.73 m2
Mild impairment
eGFR Z60 to o90
mL/min/1.73 m2
Moderate impairment
eGFR Z30 to o60
mL/min/1.73 m2
Mild-moderate
eGFR Z45 to o60
mL/min/1.73 m2
Moderate-severe
eGFR Z30 to o45
mL/min/1.73 m2
No. of patients at
baseline
275 598 157 130 27
No. of patients at
Week 52
247 553 141 119 22
Hematocrit, %
Baseline 42.16 (3.58) 41.39 (3.71) 40.24 (4.13) 40.59 (4.03) 38.56 (4.27)
Change at Week 52 2.02 (1.72 to 2.32)§ 2.31 (2.13 to 2.48)§,‡ 2.32 (1.97 to 2.66)§ 2.38 (2.01 to 2.75)§ 1.98 (0.99 to 2.97)§
BUN, mg/dL
Baseline 12.79 (3.29) 15.11 (3.70) 18.62 (4.51) 17.85 (4.00) 22.33 (5.02)
Change at Week 52 1.96 (1.55 to 2.38)§ 2.04 (1.74 to 2.35)§ 1.67 (1.01 to 2.32)§ 1.79 (1.07 to 2.51)§ 1.00 (0.62 to 2.62)
BUN/Cr, g/g Cr
Baseline 22.41 (6.93) 20.45 (5.63) 18.08 (4.76) 18.12 (4.77) 17.90 (4.79)
Change at Week 52 3.05 (2.29 to 3.81)§ 2.76 (2.34 to 3.19)§ 1.58 (0.87 to 2.30)§ 1.84 (1.03 to 2.64)§ 0.20 (1.24 to 1.64)
ALT, IU/L/371C
Baseline 30.4 (18.9) 27.5 (16.2) 25.7 (15.9) 26.2 (16.2) 23.3 (14.4)
Change at Week 52 6.4 (8.2 to 4.5)§ 5.0 (6.0 to 4.1)§ 3.8 (5.3 to 2.2)§ 3.8 (5.5 to 2.0)§ 3.8 (7.1 to 0.5)†
AST, IU/L/371C
Baseline 25.7 (10.0) 26.0 (10.1) 26.6 (11.6) 27.1 (12.0) 24.1 (9.3)
Change at Week 52 2.2 (3.2 to 1.1)§ 2.0 (2.6 to 1.3)§ 2.0 (3.3 to 0.6)† 2.1 (3.6 to 0.5)† 1.5 (3.9 to 0.8)
Creatinine, mg/dL
Baseline 0.586 (0.100) 0.754 (0.119) 1.051 (0.189) 1.003 (0.137) 1.282 (0.230)
Change at Week 52 0.014 (0.007 to 0.020)§ 0.005 (0.001 to 0.011) 0.013 (0.005 to 0.031) 0.011 (0.007 to 0.029) 0.024 (0.048 to 0.095)
Uric acid, mg/dL
Baseline 4.91 (1.20) 5.34 (1.27) 6.03 (1.35) 5.94 (1.30) 6.43 (1.55)
Change at Week 52 0.49 (0.59 to 0.39)§ 0.48 (0.55 to 0.40)§ 0.35 (0.51 to 0.18)§ 0.37 (0.54 to 0.19)§ 0.23 (0.73 to 0.28)
Cystatin C, mg/L
Baseline 0.65 (0.08) 0.77 (0.11) 1.04 (0.23) 0.99 (0.20) 1.27 (0.21)
Change at Week 52 0.03 (0.02 to 0.04)§ 0.04 (0.04 to 0.05)§ 0.07 (0.06 to 0.09)§ 0.07 (0.05 to 0.08)§ 0.11 (0.05 to 0.16)§
eGFR, mL/min/1.73 m2
Baseline 103.52 (12.72) 75.63 (8.13) 51.88 (6.64) 54.30 (3.96) 40.19 (3.96)
Change at Week 52 2.10 (3.27 to 0.94)§ 0.23 (0.40 to 0.85) 0.13 (1.05 to 0.78) 0.08 (1.09 to 0.93) 0.41 (2.75 to 1.93)
(continued)
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Table V. (continued).
Normal
eGFR Z90
mL/min/1.73 m2
Mild impairment
eGFR Z60 to o90
mL/min/1.73 m2
Moderate impairment
eGFR Z30 to o60
mL/min/1.73 m2
Mild-moderate
eGFR Z45 to o60
mL/min/1.73 m2
Moderate-severe
eGFR Z30 to o45
mL/min/1.73 m2
Urinary NAG (Cr-
corrected), U/g Cr
Baseline 8.62 (4.95) 8.54 (5.35) 10.87 (8.52) 10.07 (6.97) 14.74 (13.27)
Change at Week 52 1.06 (0.46 to 1.67)§ 1.39 (0.98 to 1.79)§ 0.52 (0.40 to 1.45) 0.92 (0.09 to 1.74)† 1.60 (5.66 to 2.46)
Urinary β2 microglobulin
(Cr-corrected),
μg/g Cr
Baseline 179.8 (198.8) 223.0 (403.9) 581.3 (1707.8) 464.1 (1721.3) 1145.8 (1548.9)
Change at Week 52 43.2 (15.5 to 70.9)† 123.3 (54.6 to 192.1)§ 299.9 (133.6 to 466.1)§ 282.4 (118.8 to 446.0)§ 394.3 (244.4 to 1032.9)
Urinary albumin (Cr-
corrected), mg/g Cr
Baseline 36.4 (65.2) 49.5 (257.5) 172.3 (561.9) 126.1 (513.4) 394.8 (724.3)
Change at Week 52 3.2 (8.5 to 2.1) 3.5 (11.9 to 19.0) 27.4 (88.2 to 33.4) 14.7 (81.1 to 51.6) 95.7 (257.6 to 66.1)
Acetoacetic acid, μmol/L
Baseline 33.6 (25.6) 33.9 (23.8) 38.7 (36.0) 37.9 (34.8) 42.7 (42.0)
Change at Week 52 31.5 (23.6 to 39.3)§ 20.8 (17.2 to 24.4)§ 16.8 (9.0 to 24.6)§ 17.0 (8.8 to 25.2)§ 15.8 (9.9 to 41.5)
β-hydroxybutanoic acid,
μmol/L
Baseline 70.2 (64.9) 76.1 (72.3) 97.7 (113.7) 93.1 (112.0) 119.9 (121.4)
Change at Week 52 93.7 (63.9 to 123.5)§ 53.4 (41.7 to 65.1)§ 33.3 (10.2 to 56.5)† 37.0 (11.5 to 62.5)† 13.5 (44.6 to 71.5)
ALT ¼ alanine aminotransferase; AST ¼ aspartate aminotransferase; BUN ¼ blood urea nitrogen; Cr ¼ creatinine; eGFR ¼ estimated glomerular ﬁltration rate; NAG ¼
N-acetyl-β-D-glucosaminidase.
*Data are presented as means (SD) for baseline values and as means (95% CI) for changes at Week 52.
†P o 0.05 versus baseline, based on 1-sample t test.
‡n ¼ 552.
§P o 0.001 versus baseline, based on 1-sample t test. M
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Clinical TherapeuticsAnother ﬁnding of interest from our analysis was
that the decrease in body weight was signiﬁcantly
reduced in patients with moderate renal impairment,
but the body weight-reducing efﬁcacy of luseogliﬂozin
was much less diminished than its HbA1c-lowering
efﬁcacy. The amount of body weight-reducing efﬁcacy
in patients with moderate renal impairment was
76.0% versus that shown in patients with normal
renal function, whereas the amount of HbA1c-
reducing efﬁcacy was lower by nearly half. Further-
more, the change in body weight at Week 52 was
about 3% even in patients with moderate renal
impairment. Therefore, luseogliﬂozin could be beneﬁ-
cial in obese patients with T2DM with renal impair-
ment, given that obesity is associated with decreases in
renal function.30
The somewhat different HbA1c and body weight
outcomes relative to renal function appear to be
discrepant with the results of earlier pharmacologic
studies on renal impairment, which have shown
that the daily UGE was decreased with declining
eGFR,18–22 with corresponding decreases expected in
HbA1c or body weight mainly due to calorie loss with
UGE. This discrepancy may be because there are more
factors involved in decreases in HbA1c (blood glu-
cose) and body weight than just UGE. The decrease in
blood glucose with SGLT2 inhibition represents the
result of UGE and compensatory hepatic glyconeo-
genesis, whereas the amount of weight loss with
SGLT2 inhibition represents the balance between
UGE (calorie loss), calorie intake with meals, and
the basal metabolism as determined by multiple
factors, including body weight. Different sets of
hormones are implicated in the regulation of blood
glucose and body weight, and these may account for
different thresholds for HbA1c and body weight
outcomes. Further research is needed before conclu-
sions can be made.
Although glucose control in patients with T2DM
with nephropathy is crucial to preventing the pro-
gression of nephropathy,31–35 the risk–beneﬁt proﬁle
of hypoglycemic agents should be considered. In our
Phase III study in patients with moderate renal
impairment (Study 1), luseogliﬂozin offered an accept-
able tolerability and safety proﬁle, with no critical
issues identiﬁed over the 52-week study. Our pooled
analysis (Study 2) showed that the incidences of AEs
and adverse drug reactions did not differ between
patients with lower baseline eGFR versus other levels.84However, the incidence of serious AEs and AEs
leading to discontinuation tended to be slightly higher
in patients with moderate-severe renal impairment
(eGFR Z30 to o45 mL/min/1.73 m2) than in the
other groups. The demographic characteristics
showed that patients with lower eGFR tended to be
older, have a longer duration of diabetes, a higher rate
of diabetic complications and complications of hyper-
tension, and a higher rate of use of antihypertensive
agents and diuretic agents, indicating that patients
with lower eGFR may have poorer general health
status and a higher risk of AEs, which may account
for the high incidence of serious AEs and AEs leading
to discontinuation in those with moderate-severe renal
impairment.
In addition, given the pharmacologic mechanism of
action of SGLT2 inhibitors, a potential risk may exist
for volume depletion associated with the diuretic effects
of UGE. The incidence of AEs related to volume
depletion tended to be higher in patients with
moderate-severe renal impairment, although the
changes in Ht levels in these patients were similar to
those in the other groups, and Ht and BUN were
observed to increase until Week 12 and became stable
thereafter (Supplemental Figure S6 in the online version
at http://dx.doi.org/10.1016/j.clinthera.2015.10.025).
However, patients with renal impairment may be at
risk for dehydration due to impaired water homeostasis.
Therefore, in patients with decreased eGFR, the use of
SGLT2 inhibitors requires caution with respect to the
health status of each individual patient, and monitoring
for volume depletion and dehydration, especially in the
early treatment phase, is necessary.
Although initial transient decreases in eGFR, which
are similarly seen with other SGLT2 inhibitors, were
seen after treatment with luseogliﬂozin, eGFR was
thereafter immediately increased to slightly above the
baseline level in all groups. Especially, in patients with
mild and moderate renal impairment, eGFR was not
decreased by 52 weeks of treatment with luseogliﬂo-
zin. In contrast, eGFR appeared to be slightly de-
creased from baseline throughout the treatment with
other SGLT2 inhibitors in patients with renal impair-
ment,26,27 suggesting that these could have a different
effect on eGFR from luseogliﬂozin. Although the
reasons for the variations observed with luseogliﬂozin
after Week 4 (eGFR was increased above the baseline
level and decreased thereafter) remain unclear,
1 reason could be the involvement of seasonalVolume 38 Number 1
M. Haneda et al.variations, given that many patients included in this
analysis tended to start and ﬁnish treatment during the
summer when eGFR levels have a tendency to be
decreased.36 Furthermore, although our analysis
showed that eGFR was signiﬁcantly decreased at
Week 52 in those with normal renal function, a
subanalysis showed that eGFR tended to be
decreased particularly in those with baseline eGFR
Z120 mL/min/1.73 m2. Because elevated GFR is
caused by intraglomerular hypertension, which, in
turn, may lead to nephron loss,37 our ﬁndings could
suggest a favorable effect of luseogliﬂozin in those
presenting with hyperﬁltration by decreasing eGFR.
This result could be in part in agreement with a
previous study that showed that empagliﬂozin
attenuated renal hyperﬁltration in patients with type
1 diabetes mellitus, likely by affecting tubular-
glomerular feedback mechanisms.38 Long-term studies
are required to conﬁrm these ﬁndings.
The decreases in blood pressure observed with
luseogliﬂozin in our analysis were consistent with those
reported in previous studies14–17; however, this analysis
clariﬁed for the ﬁrst time that blood pressure decreased
to a similar degree in all eGFR groups. Furthermore, the
Japanese Guideline for the Management of Hyper-
tension 201439 recommends controlling blood
pressure under 130/80 mm Hg for patients with
T2DM. Our subgroup analysis showed that the
decrease in blood pressure was greater in those with
baseline SBP Z130 mm Hg, and the degree of its
decrease was also similar across all eGFR groups.
Because controlling hypertension in patients with
nephropathy is crucial to preventing the progression
of nephropathy and decreasing the incidence of
cardiovascular disease,40 the inﬂuence of luseogliﬂozin
on blood pressure might be beneﬁcial and efﬁcient for
patients with T2DM with nephropathy.
Our study in patients with moderate renal impair-
ment and our pooled analysis both have several
limitations. The sample size, especially the number of
patients with moderate-severe renal impairment (eGFR
Z30 to o45 mL/min/1.73 m2), was small, and the
treatment period was limited to 52 weeks. Our pooled
analysis included open-label studies, in accordance
with the Japanese Guidelines for Clinical Trials and
New Drug Application. Therefore, the characteristics
of the patients as stratiﬁed by eGFR varied between the
groups, and the patients with lower eGFR may have
had poorer general health status, and eGFR may haveJanuary 2016been correlated with patient age, which may have
affected the results of the present analysis. Moreover,
the combination therapies are a confounding factor in
this simple pooled analysis that did not assign weight
to each data point but treated data as if derived from a
single sample. Hence, the positive efﬁcacy results may
not be due to luseogliﬂozin alone. Again, luseogliﬂozin
should be investigated in a variety of patient popula-
tions to establish its long-term safety and efﬁcacy
proﬁle, as well as to elucidate prognostic factors for
its efﬁcacy and safety.CONCLUSIONS
Luseogliﬂozin decreased glycemic parameters and
body weight in Japanese patients with T2DM with
moderate renal impairment compared with placebo,
and these results were conﬁrmed throughout the
52-week treatment period. Moreover, luseogliﬂozin
was shown to offer an acceptable safety proﬁle in
these patients. The pooled analyses of 4 Phase III
studies showed that treatment with luseogliﬂozin
signiﬁcantly improved glycemic control and reduced
body weight in all patients groups, irrespective of their
baseline eGFR. Baseline eGFR was shown to inﬂuence
the reduction in HbA1c with luseogliﬂozin, with
diminished efﬁcacy in patients with moderate renal
impairment. Luseogliﬂozin was well tolerated and safe
in patients with varying renal function, with no
signiﬁcant safety issues identiﬁed for these patients,
regardless of baseline eGFR. Future studies are re-
quired to conﬁrm these ﬁndings.ACKNOWLEDGMENTS
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Study 1 (TS071-03-4): A 52-week study in patients
with moderate renal impairment
Patients
Inclusion criteria
Patients who fulﬁlled the following criteria:
1) Patients with HbA1c Z 6.5% to r 10.0%
(Japan Diabetes Society [JDS] value) (corresponding
to Z 6.9% to r 10.5% in National Glycohemglobin
Standardization Program (NGSP)) at weeks -4 and -2,
and with changes within 1.0%
2) Patients with eGFR (mL/min/1.73 m2) Z 30 to
o 60 at weeks -4 or -2
3) Patients treated with regular diet therapy Z 8
weeks prior to week -4
4) Patients diagnosed with type 2 diabetes, treated
without hypoglycemic agents, or treated with 1 to 2
oral hypoglycemic agents (OHAs) with stable dosages
Z 8 weeks prior to week -4
5) Outpatients
6) Males or females, aged Z 20 years (at the time
of informed consent)
7) Patients who were explained the study details,
understood the study details, and voluntarily provided
written consent for participation in this study
Exclusion criteria
Patients who fulﬁlled any of the following criteria:
1) With diabetes mellitus except type 2 (patients
with type 1 diabetes mellitus, gestational diabetes
mellitus, and/or other types of diabetes mellitus arising
from other medical conditions)
2) Patients with endocrine diseases, such as thyroid
dysfunction, that would affect glucose levels
3) Patients with disorders of the renal tubules, such
as Fanconi’s syndrome and/or interstitial nephritis
4) Patients with renal failure and severe proteinu-
ria, with blood albumin r 3.0 g/dL at weeks -2 or -4
5) Patients with history of dialysis therapy within a
year at week -4 or diagnosed as requiring dialysis
6) Patients with history of renal excision and/or
renal transplantation
7) Patients with renal tract or genital infection
8) Patients with apparent urinary disorders due to
neurogenic bladder and/or prostate hyperplasia
9) Patients with anemia treated with erythropoietin
10) Patients with uncontrolled high blood pressure
4 170 mm Hg SBP or4 100 mm Hg diastolic blood
pressure (DBP) at weeks -4 or -2January 201611) Patients with alanine aminotransferase (ALT)
or aspartate aminotransferase (AST) Z 2.5 times
upper limit of normal (ULN) at weeks -4 or -2
12) Patients with serious digestive dysfunction, or
with surgical history with marked effect on digestive
and absorptive function
13) Patients with serious cardiovascular, circula-
tory, or cerebrovascular disorders; pancreatic dysfunc-
tion; and/or hemodyscrasia
14) Patients with unstable psychiatric conditions
that could affect normal informed consent and con-
tinuation in the study
15) Patients with malignant tumors or with history
of malignant tumors, except those who completed
treatment for malignant tumors and are thought to be
free of recurrences
16) Patients with severe allergic reactions
17) Patients treated with insulin and/or glucagon-
like peptide-1 agonist within 8 weeks prior to week -4
18) Patients who changed the dosage of OHAs
within the observational period (from weeks -4 to 0)
19) Patients who require changes in dosage, addi-
tional agents, or changes in anti-hypertensive agents
or diuretics within the observational period
20) Patients who have been treated with the follow-
ing agents at the start of the study, or those in need of
treatment with the following agents in the study period spherical carbonaceous adsorbent
 adrenal cortical steroids (except for topical use)
21) Patients treated with other investigational
agents within 12 weeks prior to week -4
22) Patients with history of luseogliﬂozin treatment
23) Patients with chronic high alcohol consumption
(whose daily average alcohol intake exceeded 100 mL/
day)
24) Female patients who were pregnant, lactating,
or with likelihood of pregnancy; or who intended to
conceive; or refused to take birth control measures
during the study period
25) Other conditions considered to be unsuitable
by the attending physician
Method of recruitment of participants
TS071-03-4 is a multi-center phase III study. Each
site and investigator is contracted by the sponsor,
Taisho Pharmaceutical. Physicians registered as inves-
tigators obtained written informed consent from88.e1
Clinical Therapeuticspatients who met the screening criteria. The patients
who cleared the criteria were registered formally at the
individual central registration ofﬁce after conﬁrming
their clearing of the screening criteria and informed
consent. The registration was implemented on a ﬁrst-
come-ﬁrst basis. When the participants reached the
targeted number, recruitment was stopped. On
TS071-03-1 and 03-4 trials, including placebo-con-
trolled, randomized double-blinded phases, the allo-
cations were implemented at the individual central
registration ofﬁce.
Assessment
The primary efﬁcacy outcomes were changes in
hemoglobin A1c (HbA1c), fasting plasma glucose
(FPG), and body weight from baseline to week 52.
Changes in glycoalbumin (GA) levels, fasting insulin
levels, C-peptide immunoreactivity (CPR) levels, intact
proinsulin levels, HOMA-R, and HOMA-β were also
evaluated. For safety outcomes, AEs including abnor-
mal changes in laboratory values and vital signs were
evaluated. All efﬁcacy and safety clinical laboratory
tests were conducted centrally at Mitsubishi Chemical
Medience Corporation (currently LSI Medience Cor-
poration), Tokyo, Japan. The assessment methods for
HbA1c and plasma glucose levels included the addi-
tion of NaF and EDTA-2Na, storage in cold storage,
and measurement by the enzymatic method. All AEs
were evaluated throughout the study periods and were
coded using Medical Dictionary for Regulatory Activ-
ities (MedDRA/J) version 15.0 by System Organ Class
and Preferred Term. AEs were presented as the
number (%) of patients with each AE. All AEs were
assessed for their causal relationship to the study drug
(deﬁnitely related, probably related, possibly related,
unrelated, or unknown) as well as for severity (mild,
moderate, or severe).
Statistical analysis
For the evaluation of HbA1c, FPG, and GA, analysis
of covariance was carried out using the value at the start
of the double-blind treatment period as the covariate,
and for the evaluation of other efﬁcacy end-points, two-
sample t-test was applied. When data were missing or
deemed unacceptable at week 24 (the end of the double-
blind treatment period), the last observation carried
forward (LOCF) method was applied. In addition, for
the 52-week period, intragroup mean changes from
baseline for individual efﬁcacy endpoints were evaluated88.e2by the one-sample t-test (missing or unacceptable data
were not imputed). All tests were conducted with a 2-
sided alpha level of 0.05. All analyses were conducted
using SAS v9.2 (Cary, NC, USA).
Study 2: Pooled analysis
Patients
Study 2 is the pooled analysis of four studies
(TS071-03-1, 03-2, 03-3, and 03-4).
The following are the inclusion and exclusion
criteria of TS071-03-1, 03-2, and 03-3:
Inclusion criteria
Patients who fulﬁlled the following criteria:
1) Patients with HbA1cZ 6.5% tor 10.0% (JDS)
(corresponding to Z 6.9% to r 10.5% in NGSP) at
weeks -4 and -2, with changes within 1.0%
2) Patients treated with regular diet therapy Z 8
weeks prior to week -4
3) Outpatients
4) Males or females, aged Z 20 years (at the time
of informed consent)
5) Patients who were explained the study details,
understood the study details, and voluntarily provided
written consent for participation in this study
6) Patients treated only with glimepiride within
approved and stable dosagesZ 8 weeks prior to week
-4 (TS071-03-1); patients treated only with another
OHA (biguanide, α-glucosidase inhibitors, thiazoli-
dine, DPP-4 inhibitor, or glinide) within approved
and stable dosageZ 8 weeks prior to week -4 (TS071-
03-2).
Exclusion criteria
Patients who fulﬁlled any of the following criteria:
1) Patients with diabetes mellitus except type 2
(patients with type 1 diabetes mellitus, gestational
diabetes mellitus, and/or other types of diabetes
mellitus arising from other medical conditions)
2) Patients with endocrine diseases, such as thyroid
dysfunction, that would affect glucose levels
3) Patients with history of renal excision and/or
renal transplantation
4) Patients with renal diseases that need aggressive
treatment with corticosteroid agents and/or immunosup-
pressive drugs
5) Patients with renal tract or genital infection
6) Patients with apparent urinary disorders due to
neurogenic bladder and/or prostate hyperplasiaVolume 38 Number 1
M. Haneda et al.7) Patients with ALT or AST Z 2.5 times ULN at
weeks -4 or -2
8) Patients with uncontrolled high blood pressure
4170 mm Hg SBP or 4100 mm Hg DBP at weeks
-4 or -2
9) Patients with serious digestive dysfunction, or
with surgical history with marked effect on digestive
and absorptive function
10) Patients with serious cardiovascular, circula-
tory, or cerebrovascular disorders; pancreatic dysfunc-
tion; and/or hemodyscrasia
11) Patients with severe diabetic microangiopathy,
such as pre-proliferative or proliferative diabetic
retinopathy
12) Patients with malignant tumors or with history
of malignant tumors, except those who completed
treatment for malignant tumors and are thought to be
free of recurrences
13) Patients with severe allergic reactions
14) Patients treated with insulin or OHAs except
glimepiride (TS071-03-1), treated with insulin or
other OHAs except co-administered OHA prior to
study entry (TS071-03-2), or treated with insulin or
OHAs (TS071-03-3)
15) Patients with unstable psychiatric conditions
that could affect normal informed consent and con-
tinuation in the studyJanuary 201616) Patients with a history of luseogliﬂozin
treatment
17) Patients treated with other investigational
agents within 12 weeks prior to week -4
18) Patients with chronic high alcohol consumption
(whose daily average alcohol intake exceeded 100
mL /day)
19) Female patients who were pregnant, lactating,
or with likelihood of pregnancy; or who intended to
conceive; or refused to take birth control measures
during the study period
20) Patients with eGFR o 45 mL/min/1.73 m2 at
weeks -2 and -4
21) Patients who require changes in dosage, addi-
tional agents, or changes in anti-hypertensive agents
within the observational period
22) Patients who change the dosage of glimepiride
within the observational period (TS071-03-1), or
patients who change the dosage of another co-
administrated OHA within the observational period
(TS071-03-2)
23) Other conditions considered to be unsuitable
by the attending physician
Assessment and Method of recruitment of participants
The major assessments and method of recruitment
of participants are the same as in TS071-03-4.88.e3
 Pooled population
Four phase III studies (TS071-03-1,03-2,03-3,03-4)
n = 1152
Excluded
Patients who received placebo in
double-blind period (in TS071-03-1
or 03-4 studies)
Patients whose eGFR baseline was
<30mL/min/1.73 m  (in TS071-03-4 study)
n = 122
n = 121
n = 1
Pooled analysis set
Patients whose baseline eGFR ≥30
Patients who recived luseogliflozin at least once
n = 1030
at week 0
Normal
renal function
(baseline eGFR
≥90)
n = 275
Mild
renal impairment
(baseline eGFR
≥60 to <90)
n = 598
Moderate
renal impairment
(baseline eGFR
≥30 to <60)
n = 157
Mild-moderate
(baseline eGFR
≥45 to <60)
n = 130
Moderate-severe
(baseline eGFR
≥30 to <45
n = 27
Normal
renal funtion
Completed
52 weeks
treatment period
n = 247
Mild
renal impairment
Completed
52 weeks
treatment period
n = 553
Moderate
renal impairment
Completed
52 weeks
treatment period
n = 141
Mild-moderate
Completed
52 weeks
n = 119
Moderate-severe
Completed
52 weeks
n = 22
week 0 week 24 week 52
Open-label study
Open-label study
Open-label phase
Open-label phase
TS071-03-3 study
Luseogliflozin
TS071-03-2 study
TS071-03-4 study
Luseogliflozin on
Monotherapy
Add-on therapy
TS071-03-1 study
Add-on therapy
to other OHAs
to sulfonylurea
patients with
renal impairment
Double-blind phase
Luseogliflozin 2.5 mg/day
Luseogliflozin 2.5 mg/day
Luseogliflozin 2.5 mg/day
Luseogliflozin 2.5 mg/day
Luseogliflozin 2.5 mg/day
Luseogliflozin 2.5 mg/day
Luseogliflozin 2.5 mg/day
Luseogliflozin 2.5 mg/day
Luseogliflozin 2.5 mg/day
Luseogliflozin 2.5 mg/day
Rando-
mization
Rando-
Placebo
mization
BG, DPP4 inhibitor, TZD, Glinide, or α-GI
Double-blind phase
SU
SU
Up to two oral hypoglycemic agents
Up to two oral hypoglycemic agents
Increased to Luseogliflozin 5 mg/day
Increased to Luseogliflozin 5 mg/day
Increased to Luseogliflozin 5 mg/day
Increased to Luseogliflozin 5 mg/day
Increased to Luseogliflozin 5 mg/day
Increased to Luseogliflozin 5 mg/day
Placebo
A B
Figure S1. (A) Patient disposition in the pooled analysis (Study 2). (B) Four luseogliflozin arms in four studies
included in the pooled analysis (Study 2). Boxed arms were included in the pooled analysis. α-GI =
α-glucosidase inhibitor; BG = biguanide; DPP4i = dipeptidyl-peptidase 4 inhibitor; eGFR =
estimated glomerular filtration rate; RCT = randomized controlled trial; SU = sulfonylurea;
TZD = thiazolidinedione.
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Informed Consent
n = 246
Excluded
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Criterion A
Criterion B
28-week open-label phase    
24-week double-blind phase    
Randomized
n = 145
Placebo
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  2
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n = 3
n = 48 n = 89
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n = 45 n = 83
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Figure S2. Consort diagram (Study 1: Phase III study in patients with moderate renal impairment). Exclusion
criteria before randomization: Criterion A: Did not meet selection criteria or exclusion criteria
applied. Criterion B: Voluntary withdrawal by subject. Exclusion criteria during the 24-week
double-blind and 28 week open-label phases: Criterion 1: Continuation difficult due to adverse
events. Criterion 9: Despite increase in dose of luseogliflozin to 5 mg, HbA1c at 12 weeks after
dose increase was ≥ +1.0% higher than pre-dose increase HbA1c. Criterion 12: Withdrawal
requested by subject due to adverse events. Criterion 13: Withdrawal request by subject (unrelated
to adverse events). Criterion 15: Other; continuation difficulty as assessed by principal investigator
or sub-investigator.
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Figure S3. (A) Changes in HbA1c, (B) FPG, and
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Figure S5. Changes in eGFR as stratified by baseline eGFR in patients with normal renal function (Study 2:
pooled analysis). (Top) Changes in eGFR over time during 52 weeks as stratified by baseline eGFR.
Data are presented as means ±95% CI and change from baseline. (Bottom) Changes in eGFR at
week 52 as stratified by baseline eGFR. Data are presented as means ± SD for baseline values and
as means (95% CI) for changes at week 52. *P o 0.05 versus baseline, 1-sample t test. CI =
confidence interval; eGFR = estimated glomerular filtration rate; SD = standard deviation.
M. Haneda et al.
January 2016 88.e7
Normal (eGFR ≥90), n = 275 Mild (eGFR ≥60 to <90), n = 598
Moderate (eGFR ≥30 to <60), n = 157
Change in SBP (mm Hg) Change in DBP (mm Hg)
4
2
0
-2
-4
-6
-8
-10
0 4 8 12 16 20 36 52484440322824
0 4 8 12 16 20 36 52484440322824
0 4 8 12 16 20 36 52484440322824
0 4 8 12 16 20 36 52484440322824
 3
 2 
 1
 0
 -1
 -2
 -3
 -4
 -5
 4 
 3
 2
 1
0
4
3
2
1
0
Treatment period (week) Treatment period (week)
Treatment period (week)Treatment period (week)
Change in Ht (%) Change in BUN (mg/dL)
A B
C D
Figure S6. (A) Changes in SBP, (B) DBP, (C) Ht, and (D) BUN over time during 52 weeks among eGFR
groups (Study 2: pooled analysis). Data are presented as means ± 95% CI and changes from
baseline. BUN = blood urea nitrogen; CI = confidence interval; DBP = diastolic blood pressure;
eGFR = estimated glomerular filtration rate; Ht = hematocrit; SBP = systolic blood pressure.
Clinical Therapeutics
88.e8 Volume 38 Number 1
Supplemental Table SI. Demographic and baseline characteristics of patients (Study 1: Phase III study in
patients with moderate renal impairment).
Placebo* Luseogliﬂozin† Total
Test‡n ¼ 50 n ¼ 95 n ¼ 145
Male, n (%) 39 (78.0) 72 (75.8) 111 (76.6) χ2 ¼ 0.089 p ¼ 0.765
Age (mean  SD), y 68.4  8.9 67.9  8.9 68.0  8.9 T ¼ -0.345 p ¼ 0.731
o 65, n (%) 14 (28.0) 32 (33.7) 46 (31.7) χ2 ¼ 0.489 p ¼ 0.485
Z 65, n (%) 36 (72.0) 63 (66.3) 99 (68.3)
Body weight (mean  SD), kg 67.77  11.79 66.90  13.60 67.20  12.97 T ¼ -0.384 p ¼ 0.702
BMI (mean  SD), kg/m2 25.81  3.95 25.45  4.18 25.58  4.09 T ¼ -0.500 p ¼ 0.618
Age at onset (mean  SD), y 55.8  10.6 57.7  10.0 57.0  10.2 T ¼ 1.059 p ¼ 0.291
Disease duration (mean  SD), y 12.6  10.4 10.4  6.9 11.1  8.3 T ¼ -1.534 p ¼ 0.127
Presence of renal complications,
n (%)
36 (72.0) 66 (69.5) 102 (70.3) χ2 ¼ 0.100 p ¼ 0.752
Past history of renal disease, n (%) 5 (10.0) 6 (6.3) 11 (7.6) χ2 ¼ 0.634 p ¼ 0.426
Complications
Diabetic complications, n (%) 33 (66.0) 60 (63.8) 93 (64.6)
Nephropathy, n (%) 26 (52.0) 52 (55.3) 78 (54.2)
Neuropathy, n (%) 9 (18.0) 17 (18.1) 26 (18.1)
Retinopathy, n (%) 21 (42.0) 20 (21.3) 41 (28.5)
Other, n (%) 2 (4.0) 7 (7.4) 9 (6.3)
Non-diabetic complications, n (%) 50 (100.0) 93 (98.9) 143 (99.3)
Hypertension, n (%) 37 (74.0) 78 (83.0) 115 (79.9)
Lipid metabolism disorder, n (%) 40 (80.0) 76 (80.9) 116 (80.6)
Heart disease, n (%) 10 (20.0) 19 (20.2) 29 (20.1)
Liver/biliary tract disease, n (%) 11 (22.0) 29 (30.9) 40 (27.8)
Renal disease, n (%) 11 (22.0) 22 (23.4) 33 (22.9)
Other, n (%) 48 (96.0) 83 (88.3) 131 (91.0)
History of hypoglycemic agents
use, n (%)
45 (90.0) 87 (91.6) 132 (91.0) χ2 ¼ 0.100 p ¼ 0.752
Concomitant oral hypoglycemic
agent
None, n (%) 6 (12.0) 8 (8.4) 14 (9.7) |Z| ¼ 0.463 p ¼ 0.643
1 agent, n (%) 19 (38.0) 46 (48.4) 65 (44.8)
2 agents, n (%) 25 (50.0) 41 (43.2) 66 (45.5)
HbA1c (mean  SD), % 7.69  0.65 7.72  0.68 7.71  0.67 T ¼ 0.212 p ¼ 0.833
o 7.0, n (%) 4 (8.0) 3 (3.2) 7 (4.8) |Z| ¼ 0.881 p ¼ 0.378
Z 7.0 to o 8.0, n (%) 35 (70.0) 68 (71.6) 103 (71.0)
Z 8.0 to o 9.0, n (%) 8 (16.0) 16 (16.8) 24 (16.6)
Z 9.0, n (%) 3 (6.0) 8 (8.4) 11 (7.6)
FPG (mean  SD), mg/dL 141.7  26.7 140.4  30.2 140.8  29.0 T ¼ -0.254 p ¼ 0.800
Glycoalbumin (mean  SD), % 20.92  3.09 20.68  3.38 20.76  3.27 T ¼ -0.422 p ¼ 0.674
Fasting insulin (mean  SD), μU/mL 8.34  5.82 7.69  6.27 7.92  6.11 T ¼ -0.600 p ¼ 0.550
Blood CPR (mean  SD), ng/mL 1.71  0.88 1.60  0.81 1.64  0.83 T ¼ -0.814 p ¼ 0.417
Creatinine (mean  SD), mg/dL 1.070  0.266 1.075  0.239 1.074  0.248 T ¼ 0.117 p ¼ 0.907
Cystatin C (mean  SD), mg/L 1.087  0.246 1.101  0.267 1.096  0.259 T ¼ 0.307 p ¼ 0.759
(continued)
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Supplemental Table SI. (continued).
Placebo* Luseogliﬂozin† Total
Test‡n ¼ 50 n ¼ 95 n ¼ 145
eGFR (mean  SD), mL/min/1.73 m2 52.4  8.2 52.0  9.4 52.1  9.0 T ¼ -0.303 p ¼ 0.762
o 30, n (%) 1 (2.0) 1 (1.1) 2 (1.4) |Z| ¼ 0.162 p ¼ 0.871
Z 30 to o 45, n (%) 6 (12.0) 23 (24.2) 29 (20.0)
Z 45 to o 60, n (%) 36 (72.0) 49 (51.6) 85 (58.6)
Z 60, n (%) 7 (14.0) 22 (23.2) 29 (20.0)
o 45, n (%) 7 (14.0) 24 (25.3) 31 (21.4) χ2 ¼ 2.472 p ¼ 0.116
Z 45, n (%) 43 (86.0) 71 (74.7) 114 (78.6)
Urinary albumin
(urine Cr-corrected)
(mean  SD), mg/g Cr
231.91 
613.89
335.67 
812.78
299.89 
749.61
T ¼ 0.791 p ¼ 0.430
o 10, n (%) 10 (20.0) 19 (20.0) 29 (20.0) |Z| ¼ 0.379 p ¼ 0.705
Z 10 to o 30, n (%) 15 (30.0) 26 (27.4) 41 (28.3)
Z 30 to o 300, n (%) 18 (36.0) 33 (34.7) 51 (35.2)
Z 300, n (%) 7 (14.0) 17 (17.9) 24 (16.6)
BMI, body mass index; CPR, C-peptide immunoreactivity; Cr, creatinine; eGFR, estimated glomerular ﬁltration rate; FPG,
fasting plasma glucose; HbA1c, hemoglobin A1c; SD, standard deviation.
χ2, chi-square test (no continuity correction); T, two-sample t-test; |Z|, Wilcoxon two-sample test.
*Group assigned to placebo in the 24-week double-blind phase.
†Group assigned to luseogliﬂozin 2.5 mg in the 24-week double-blind phase.
‡A signiﬁcance level of P o 0.15 (two-sided) was taken to indicate heterogeneity between the placebo and luseogliﬂozin
groups.
Clinical Therapeutics
88.e10 Volume 38 Number 1
Supplemental Table SII. Efficacy outcome (Study 1: Phase III study in patients with moderate renal impairment).
Placebo§ Luseogliﬂozin║ Difference (vs. placebo)
n Mean P-value n Mean P-value Mean (95%CI) P-value
HbA1c, %
Baseline 50 7.69  0.65 95 7.72  0.68 –
Change at week 24 50 0.09 (0.1, 0.3) 0.339 95 0.11 (0.2, 0.0) 0.055 0.19 (0.4, 0.0) 0.041†
Change at week 52 – 83 0.30 (0.4, 0.2) o 0.001** –
FPG, mg/dL
Baseline 50 141.7  26.7 95 140.4  30.2 –
Change at week 24 50 0.5 (5, 6) 0.851 95 6.7 (12, 1) 0.014* 7.8 (15, 1) 0.028†
Change at week 52 – 83 14.1 (19, 9) o 0.001** –
Body weight, kg
Baseline 50 67.77  11.79 95 66.90  13.60 –
Change at week 24 50 0.02 (0.4, 0.4) 0.938 95 1.29 (1.7, 0.9) o 0.001** 1.28 (1.9, 0.7) o 0.001‡
Change at week 52 – 83 2.01 (2.5, 1.5) o 0.001** –
Change at week 24 (%) 50 0.11 (0.5, 0.8) 0.736 95 1.93 (2.5, 1.3) o 0.001** 2.04 (3.0, 1.1) o 0.001‡
Change at week 52 (%) – 83 3.04 (3.8, 2.3) o 0.001** –
Glycoalbumin, %
Baseline 50 20.92  3.09 95 20.68  3.38 –
Change at week 24 50 0.38 (1.0, 0.2) 0.213 95 1.66 (2.1, 1.2) o 0.001** 1.35 (2.0, 0.7) o 0.001‡
Change at week 52 – 83 1.41 (1.9, 0.9) o 0.001** –
Fasting insulin, μU/mL
Baseline 50 8.34  5.82 95 7.69  6.27 –
Change at week 24 50 1.14 (2.2, 0.1) 0.033* 95 0.99 (1.7, 0.3) 0.007* 0.15 (1.1, 1.4) 0.813
Change at week 52 – 83 1.85 (2.6, 1.1) o 0.001** –
Blood CPR, ng/mL
Baseline 50 1.71  0.88 95 1.60  0.81 –
Change at week 24 50 0.06 (0.2, 0.1) 0.363 95 0.01 (0.1, 0.1) 0.808 0.05 (0.1, 0.2) 0.594
Change at week 52 – 83 0.15 (0.2, 0.1) 0.002* –
CI, conﬁdence interval; CPR, C-peptide immunoreactivity; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c.
Data are presented as means  SD for baseline values and as mean (95% CI) for changes at weeks 24 and 52.
*P o 0.05, **P o 0.001 (vs. baseline, 1-sample t test).
†P o 0.05, ‡P o 0.001 HbA1c, FPG, and glycoalbumin were compared using ANCOVA with their baseline
values as covariates. 2-sample t test were used for comparisons of all other outcomes.
§Group assigned to placebo in the double-blind period (ﬁrst 24 weeks).
║Group assigned to luseogliﬂozin 2.5 mg in the double-blind period (ﬁrst 24 weeks).
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Supplemental Table SIII. Safety profile (Study 1: Phase III study in patients with moderate renal impairment).
24-week double-blind phase
52-week
Placebo* Luseogliﬂozin† Luseogliﬂozin†
n ¼ 50 n ¼ 95 n ¼ 95
Adverse events 31 (62.0) 64 (67.4) 77 (81.1)
Adverse drug reactions 5 (10.0) 18 (18.9) 24 (25.3)
Deaths‡ 0 (0.0) 1 (1.1) 1 (1.1)
Serious AEs other than death 1 (2.0) 3 (3.2) 9 (9.5)
AEs leading to discontinuation 1 (2.0) 3 (3.2) 6 (6.3)
Common AEs (Z 5% in any group)
Nasopharyngitis 11 (22.0) 24 (25.3) 29 (30.5)
Increase in C-reactive protein 7 (14.0) 7 (7.4) 14 (14.7)
Constipation 3 (6.0) 8 (8.4) 10 (10.5)
Upper respiratory tract infection 4 (8.0) 3 (3.2) 9 (9.5)
Pollakiuria 0 (0.0) 6 (6.3) 6 (6.3)
Increase in urinary β2 microglobulin 1 (2.0) 2 (2.1) 5 (5.3)
Dizziness 0 (0.0) 4 (4.2) 5 (5.3)
Eczema 0 (0.0) 0 (0.0) 5 (5.3)
Increase in white blood cell count 4 (8.0) 1 (1.1) 2 (2.1)
Hypoglycemia 3 (6.0) 3 (3.2) 3 (3.2)
AEs of special interest
Hypoglycemia 3 (6.0) 3 (3.2) 4 (4.2)
Hypoglycemia 3 (6.0) 3 (3.2) 3 (3.2)
Hypoglycemia unawareness 0 (0.0) 0 (0.0) 1 (1.1)
AEs related to pollakiuria§ 1 (2.0) 6 (6.3) 6 (6.3)
AEs related to volume depletion¶ 2 (4.0) 0 (0.0) 5 (5.3)
Urinary tract infection║ 0 (0.0) 2 (2.1) 4 (4.2)
Urinary tract infection
(excluding laboratory abnormalities)
0 (0.0) 1 (1.1) 3 (3.2)
Genital infections# 0 (0.0) 1 (1.1) 2 (2.1)
AEs related to cardiovascular disorders** 1 (2.0) 2 (2.1) 9 (9.5)
AEs related to renal function 6 (12.0) 8 (8.4) 16 (16.8)
Laboratory abnormalities 5 (10.0) 2 (2.1) 9 (9.5)
Urinary albumin positive 0 (0.0) 0 (0.0) 1 (1.1)
Increase in urinary β2 microglobulin 1 (2.0) 2 (2.1) 5 (5.3)
Increase in blood creatinine 2 (4.0) 0 (0.0) 3 (3.2)
Urinary crystal positive 1 (2.0) 0 (0.0) 0 (0.0)
Increase in blood urea 0 (0.0) 0 (0.0) 2 (2.1)
Decrease in GFR 1 (2.0) 0 (0.0) 1 (1.1)
Urinary blood positive 2 (4.0) 1 (1.1) 3 (3.2)
Urinary red blood cell positive 0 (0.0) 1 (1.1) 1 (1.1)
Urinary white blood cell positive 0 (0.0) 1 (1.1) 2 (2.1)
Urinary protein positive 0 (0.0) 1 (1.1) 1 (1.1)
Urolithiasis 1 (2.0) 0 (0.0) 0 (0.0)
Nephrolithiasis 1 (2.0) 0 (0.0) 0 (0.0)
(continued)
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Supplemental Table SIII. (continued).
24-week double-blind phase
52-week
Placebo* Luseogliﬂozin† Luseogliﬂozin†
n ¼ 50 n ¼ 95 n ¼ 95
Pollakiuria 0 (0.0) 6 (6.3) 6 (6.3)
Polyuria 1 (2.0) 0 (0.0) 0 (0.0)
Neurogenic bladder 0 (0.0) 0 (0.0) 1 (1.1)
Renal cyst hemorrhage 0 (0.0) 0 (0.0) 1 (1.1)
AEs, adverse events; GFR, glomerular ﬁltration rate.
Data are presented as n (%).
*Group assigned to placebo in the 24-week double-blind phase.
†Group assigned to luseogliﬂozin 2.5 mg in the 24-week double-blind phase.
‡Pancreatic cancer.
§Pollakiuria and polyuria.
¶Thirst, increase in blood uric acid, increase in blood urea, and dehydration.
║Including laboratory abnormalities (i.e., urinary white blood cell positive and bacterial test positive) and others (i.e., cystitis
and urinary tract infection).
#Candida balanitis, genital herpes, and prostatitis.
**Edema, edema peripheral, cerebral infarction, angina pectoris, atrial ﬁbrillation, bundle branch block right, and
supraventricular tachycardia.
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Supplemental Table SIV. Safety outcome (Study 1: Phase III study in patients with moderate renal impairment).
Placebo§ Luseogliﬂozin║ Difference (vs. placebo)
n Mean P-value n Mean P-value Mean (95%CI) P-value
Hematocrit, %
Baseline 50 39.26  4.35 95 40.47  4.17 –
Change at week 24 50 0.43 (0.1, 0.9) 0.096 95 2.81 (2.3, 3.3) o 0.001** 2.38 (1.6, 3.1) o 0.001‡
Change at week 52 – 83 2.47 (2.0, 3.0) o 0.001** –
AST, IU/L/371C
Baseline 50 25.2  6.5 95 26.8  11.3 –
Change at week 24 50 1.1 (2, 0) 0.056 95 1.3 (3, 0) 0.099 0.2 (2, 2) 0.892
Change at week 52 – 83 2.0 (3, 0) 0.012* –
ALT, IU/L/371C
Baseline 50 23.3  8.7 95 25.6  16.5 –
Change at week 24 50 2.3 (4, 1) 0.006* 95 2.3 (4, 0) 0.030* 0.0 (3, 3) 0.976
Change at week 52 – 83 3.2 (5, 1) 0.004* –
γ-GTP, IU/L/371C
Baseline 50 35.3  30.3 95 39.2  32.6 –
Change at week 24 50 4.8 (8, 2) 0.004* 95 4.4 (8, 1) 0.022* 0.4 (5, 6) 0.888
Change at week 52 – 83 5.9 (9, 3) o 0.001** –
Total protein, g/dL
Baseline 50 7.32  0.44 95 7.32  0.49 –
Change at week 24 50 0.03 (0.1, 0.1) 0.540 95 0.16 (0.1, 0.2) o 0.001** 0.18 (0.1, 0.3) 0.002†
Change at week 52 – 83 0.05 (0.0, 0.1) 0.202 –
Albumin, g/dL
Baseline 50 4.38  0.25 95 4.38  0.31 –
Change at week 24 50 0.03 (0.1, 0.0) 0.385 95 0.07 (0.0, 0.1) 0.006* 0.10 (0.0, 0.2) 0.018†
Change at week 52 – 83 0.02 (0.0, 0.1) 0.563 –
Triglycerides, mg/dL
Baseline 50 148.1  74.8 95 147.7  87.8 –
Change at week 24 50 11.3 (27, 5) 0.158 95 12.1 (25, 1) 0.073 0.7 (22, 21) 0.945
Change at week 52 – 83 5.0 (29, 19) 0.673 –
HDL-C, mg/dL
Baseline 50 52.9  16.5 95 57.7  16.1 –
Change at week 24 50 2.1 (0, 4) 0.015* 95 4.8 (3, 6) o 0.001** 2.7 (0, 5) 0.038†
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Supplemental Table SIV. (continued).
Placebo§ Luseogliﬂozin║ Difference (vs. placebo)
n Mean P-value n Mean P-value Mean (95%CI) P-value
Change at week 52 – 83 2.9 (1, 5) 0.003* –
LDL-C, mg/dL
Baseline 50 119.3  23.2 95 115.1  29.0 –
Change at week 24 50 0.1 (6, 6) 0.985 95 2.4 (2, 7) 0.260 2.5 (5, 10) 0.509
Change at week 52 – 83 1.5 (5, 3) 0.472 –
LDL-C/HDL-C
Baseline 50 2.443  0.804 95 2.158  0.817 –
Change at week 24 50 0.103 (0.24, 0.03) 0.125 95 0.133 (0.22, 0.05) 0.002* 0.030 (0.18, 0.12) 0.691
Change at week 52 – 83 0.124 (0.20, 0.04) 0.003* –
Uric acid, mg/dL
Baseline 50 6.31  1.43 95 5.90  1.32 –
Change at week 24 50 0.37 (0.6, 0.2) 0.001* 95 0.29 (0.4, 0.1) 0.001* 0.08 (0.2, 0.3) 0.559
Change at week 52 – 83 0.09 (0.3, 0.1) 0.409 –
BUN, mg/dL
Baseline 50 19.7  4.5 95 18.6  4.7 –
Change at week 24 50 0.4 (1, 2) 0.501 95 2.5 (2, 3) o 0.001** 2.1 (1, 4) 0.004†
Change at week 52 – 83 2.0 (1, 3) o 0.001** –
Creatinine, mg/dL
Baseline 50 1.070  0.266 95 1.075  0.239 –
Change at week 24 50 0.007 (0.03, 0.02) 0.578 95 0.031 (0.01, 0.05) 0.003* 0.038 (0.00, 0.07) 0.027†
Change at week 52 – 83 0.056 (0.03, 0.08) o 0.001** –
Cystatin C, mg/L
Baseline 50 1.087  0.246 95 1.101  0.267 –
Change at week 24 50 0.012 (0.04, 0.01) 0.328 95 0.051 (0.03, 0.08) o 0.001** 0.063 (0.03, 0.10) 0.001†
Change at week 52 – 83 0.080 (0.06, 0.11) o 0.001** –
eGFR, mL/min/1.73 m2
Baseline 50 52.4  8.2 95 52.0  9.4 –
Change at week 24 50 1.0 (0, 2) 0.145 95 1.5 (3, 0) 0.005* 2.5 (4, 1) 0.005†
Change at week 52 – 83 2.5 (4, 1) o 0.001** –
Urinary NAG (urine Cr-
corrected), U/g Cr
(continued)
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Supplemental Table SIV. (continued).
Placebo§ Luseogliﬂozin║ Difference (vs. placebo)
n Mean P-value n Mean P-value Mean (95%CI) P-value
Baseline 50 12.50  7.91 95 12.44  9.83 –
Change at week 24 50 0.98 (2.6, 0.7) 0.235 95 0.57 (2.0, 0.9) 0.444 0.41 (1.9, 2.7) 0.732
Change at week 52 – 83 0.09 (1.4, 1.2) 0.892 –
Urinary β2 microglobulin
(urine Cr-corrected),
μg/g Cr
Baseline 50 683.2  1738.8 95 1000.6  2242.5 –
Change at week 24 50 57.3 (308, 423) 0.754 95 2020.3 (341, 3699) 0.019* 1963.1 (359, 4286) 0.097
Change at week 52 – 83 491.7 (146, 838) 0.006* –
Urinary albumin (urine
Cr-corrected), mg/g Cr
Baseline 50 231.91  613.89 95 335.67  812.78 –
Change at week 24 50 67.81 (12.7, 148.3) 0.097 95 42.71 (35.1, 120.6) 0.279 25.11 (146.5, 96.3) 0.683
Change at week 52 – 83 30.74 (121.4, 59.9) 0.502 –
SBP, mm Hg
Baseline 50 130.1  14.2 95 131.9  15.3 –
Change at week 24 50 2.1 (2, 6) 0.302 95 0.5 (4, 3) 0.757 2.6 (8, 3) 0.332
Change at week 52 – 83 4.2 (7, 1) 0.011* –
DBP, mm Hg
Baseline 50 76.6  8.9 95 74.7  10.0 –
Change at week 24 50 1.2 (4, 2) 0.397 95 0.9 (3, 1) 0.421 0.3 (3, 4) 0.878
Change at week 52 – 83 3.4 (5, 1) 0.001* –
Acetoacetic acid, μmol/L
Baseline 50 30.9  22.0 95 37.0  26.8 –
Change at week 24 50 0.8 (6, 7) 0.804 93 19.6 (9, 30) o 0.001** 18.9 (4, 34) 0.015†
Change at week 52 – 83 21.0 (14, 29) o 0.001** –
β-hydroxybutanoic acid,
μmol/L
Baseline 50 77.0  71.2 95 102.3  100.4 –
Change at week 24 50 0.6 (17, 19) 0.945 93 40.8 (13, 68) 0.004* 40.2 (1, 80) 0.047†
Change at week 52 – 83 38.0 (17, 59) 0.001* –
(continued)
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Supplemental Table SIV. (continued).
Placebo§ Luseogliﬂozin║ Difference (vs. placebo)
n Mean P-value n Mean P-value Mean (95%CI) P-value
Adiponectin, μg/mL
Baseline 50 10.80  10.66 95 10.19  5.94 –
Change at week 24 50 0.01 (0.9, 0.9) 0.989 93 0.68 (0.3, 1.1) 0.002* 0.69 (0.2, 1.5) 0.107
Change at week 52 – 83 0.63 (0.2, 1.1) 0.004* –
Leptin, ng/mL
Baseline 50 8.71  6.13 95 8.33  7.40 –
Change at week 24 50 0.32 (0.4, 1.0) 0.346 93 0.38 (0.2, 0.9) 0.172 0.06 (0.8, 0.9) 0.887
Change at week 52 – 83 0.26 (0.9, 0.4) 0.415 –
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CI, conﬁdence interval; Cr, creatinine; DBP, diastolic blood pressure;
eGFR, estimated glomerular ﬁltration rate; γ-GTP, γ-glutamyl-transpeptidase; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol;
NAG, N-acetyl-β-D-glucosaminidase; SBP, systolic blood pressure.
Data are presented as means  SD for baseline values and as mean (95% CI) for changes at weeks 24 and 52.
*P o 0.05, **P o 0.001 (vs. baseline, 1-sample t test).
†P o 0.05, ‡P o 0.001 (vs. placebo, 2-sample t test).
§Group assigned to placebo in the double-blind period (ﬁrst 24 weeks).
║Group assigned to luseogliﬂozin 2.5 mg in the double-blind period (ﬁrst 24 weeks).
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Supplemental Table SV. Subgroup analysis based on the baseline SBP (Study 2: pooled analysis).
Normal Mild impairment Moderate impairment
Baseline eGFR category, mL/min/1.73 m2 Z 90 Z 60 to o 90 Z 30 to o 60
Baseline SBP category, mm Hg o 130 Z 130 o 130 Z 130 o 130 Z 130
No. of patients at baseline, n 149 126 328 270 74 83
No. of patients at week 52, n 133 114 303 250 65 76
(% of patients at week 52, %) (53.8) (46.2) (54.8) (45.2) (46.1) (53.9)
eGFR, mL/min/1.73 m2
Baseline, mean  SD 103.94  12.52 103.03  12.98 75.84  8.06 75.38  8.24 52.73  6.39 51.12  6.81
SBP, mm Hg
Baseline, mean  SD 117.3  8.4 140.3  8.1 117.2  8.7 140.9  9.0 117.9  9.2 142.4  10.7
Change at week 52, mean (95% CI) 0.7 (2.9, 1.6) 9.5 (11.5, 7.4)** 0.6 (0.6, 1.9) 10.6 (12.0, 9.1)** 1.3 (4.5, 1.9) 9.1 (12.1, 6.2)**
CI ¼ conﬁdence interval; eGFR ¼ estimated glomerular ﬁltration rate; SBP ¼ systolic blood pressure; SD ¼ standard deviation
**P o 0.001 (vs. baseline, 1-sample t test).
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Table SVI. Changes in the laboratory parameters from baseline at week 52 for all eGFR groups who received luseogliflozin (Study 2 : pooled
analysis).
Normal Mild impairment Moderate impairment
eGFR, mL/min/
1.73 m2 Z 90 Z 60 to o 90 Z 30 to o 60
Mild-moderate Moderate-severe
Z 45 to o 60 Z 30 to o 45
No. of patients
at baseline
275 598 157 130 27
No. of patients
at week 52
247 553 141 119 22
Na, mEq/L
Baseline 139.21  1.88 139.63  1.82 139.81  2.22 139.81  2.05 139.81  2.95
Change at
week 52
0.76 (0.51, 1.01)** 0.50 (0.34, 0.65)** 0.21 (0.11, 0.52) 0.15 (0.20, 0.50) 0.50 (0.27, 1.27)
Cl, mEq/L
Baseline 101.82  2.15 102.30  2.15 102.38  2.54 102.32  2.33 102.70  3.41
Change at
week 52
0.44 (0.16, 0.72)* 0.13 (0.04, 0.29) 0.35 (0.01, 0.70) 0.27 (0.12, 0.66) 0.77 (0.13, 1.68)
Ca, mg/dL
Baseline 9.13  0.33 9.17  0.31 9.26  0.34 9.25  0.32 9.32  0.42
Change at
week 52
0.06 (0.02, 0.10)* 0.05 (0.02, 0.07)** 0.04 (0.09, 0.01) 0.03 (0.08, 0.02) 0.10 (0.24, 0.05)
K, mEq/L
Baseline 4.10  0.28 4.17  0.30 4.32  0.37 4.30  0.37 4.41  0.36
Change at
week 52
0.02 (0.06, 0.01) 0.03 (0.05, 0.00)* 0.10 (0.15, 0.05)** 0.10 (0.16, 0.04)** 0.06 (0.16, 0.03)
Mg, mg/dL
Baseline 2.10  0.16 2.14  0.16 2.14  0.19 2.14  0.19 2.14  0.21
Change at
week 52
0.11 (0.09, 0.12)** 0.10 (0.08, 0.11)** 0.13 (0.11, 0.15)** 0.13 (0.10, 0.15)** 0.14, (0.07, 0.21)**
(continued)
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Table SVI. (continued).
Normal Mild impairment Moderate impairment
eGFR, mL/min/
1.73 m2 Z 90 Z 60 to o 90 Z 30 to o 60
Mild-moderate Moderate-severe
Z 45 to o 60 Z 30 to o 45
P, mg/dL
Baseline 3.27  0.42 3.26  0.45 3.28  0.45 3.27  0.46 3.33  0.38
Change at
week 52
0.10 (0.06, 0.15)** 0.10 (0.07, 0.13)** 0.07 (0.01, 0.13)* 0.05 (0.01, 0.12) 0.14 (0.02, 0.29)
BAP, μg/L
Baseline 15.51  6.44 14.52  5.59 14.55  6.36 14.38  6.38 15.37  6.29
Change at
week 52
0.59 (1.16, 0.02)* 0.85 (1.09, 0.61)** 0.90 (1.62, 0.18)* 0.79 (1.61, 0.02) 1.45 (2.93, 0.03)
NTx, nM BCE/L
Baseline 15.14  4.90 15.88  4.89 16.54  7.10 16.42  7.40 17.14  5.50
Change at
week 52
2.11 (1.54, 2.67)** 1.88 (1.52, 2.24)** 3.11 (2.39, 3.83)** 2.76 (1.99, 3.52)** 5.03 (2.98, 7.07)**
1α, 25-(OH)2
vitamin D,
pg/mL
Baseline 67.84  27.88 62.01  27.18 50.32  22.36 52.29  22.36 40.85  20.13
Change at
week 52
4.38 (8.55, 0.22)* 6.19 (8.58, 3.80)** 2.43 (6.43, 1.56) 2.50 (7.02, 2.02) 2.09 (10.44, 6.26)
Intact PTH,
pg/mL
Baseline 47.70  16.38 45.82  15.67 50.99  19.69 49.65  19.32 57.48  20.51
Change at
week 52
3.53 (1.85, 5.20)** 2.99 (2.13, 3.85)** 3.98 (2.09, 5.86)** 3.39 (1.46, 5.33)** 7.14 (0.86, 13.42)*
BAP, bone-speciﬁc alkaline phosphatase; Ca, calcium; CI, conﬁdence interval; Cl, chloride; eGFR, estimated glomerular ﬁltration rate; K, potassium; Mg, magnesium;
Na, sodium; P, phosphorus; NTx, N-terminal crosslinking telopeptide of type I collagen; PTH, parathyroid hormone ; SD, standard deviation.
Data are presented as means  SD for baseline values and as means (95% CI) for changes at week 52.
*P o 0.05, **P o 0.001 (vs. baseline, 1-sample t test).
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